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A World-Wide Problem
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Orange County Convention Center, Hall E1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1030-185 Reaching Target Lipid Goals Despite a Greater Burden 
of Disease: Lipid Control Among Minority Populations 
in East Harlem
Rachel Levine Berger, Mary Ann McLaughlin, Stephen K. Williams, Samprit Chatterjee, 
Leah Tuzzio, Jane Sisk, Mount Sinai School of Medicine, New York, NY, New York 
University, New York, NY
Background: Despite overwhelming evidence that lipid-lowering therapy signiﬁcantly 
reduces mortality and cardiovascular events, national data suggest that dyslipidemia 
remains underdiagnosed and undertreated. This contributes to the signiﬁcant disparity in 
health-related outcomes among minority populations.
Hypothesis:  This study assessed the hypothesis that Black and Hispanic patients are 
less likely to have lipid proﬁles that meet National Cholesterol Eduction Program (NCEP) 
guidelines than White patients.
Methods:  We reviewed charts of 325 Black, Hispanic, and White hypertensive patients in 
an urban general adult medicine clinic. Data from the previous two years were evaluated 
for the values of a recent lipid proﬁle, comorbidities, and treatment for hyperlipidemia. The 
low-density lipoprotein cholesterol (LDL-C) goals for each patient were deteremined as 
deﬁned by NCEP guidelines. The primary end point was the success rate of each ethnic 
group in meeting these goals.
Results: Of 325 patients, 88.6% had a lipid proﬁle within the last two years. Overall, 54% 
had an LDL-C goal of <100 mg/dl, 31% had a goal of <130 mg/dl, and 14.7% had a goal 
of <100 mg/dl (p=.003). The overall achievement of LDL-C goals was 49.69% for those 
with a goal <100 mg/dl, 68% for < 130 mg/dl, and 93.81% for <160 mg/dl, and did not vary 
signiﬁcantly by ethnicity.
Conclusions: Although this study population has more patients meeting NCEP guidelines 
for lipid control than national data, almost 40% of patients have not met these target 
goals. Blacks and Hispanics, two groups that have traditionally been underdiagnosed and 
undertreated, were signiﬁcantly more likely than Whites to have an LDL goal of <100 
mg/dl. Despite having a greater burden of illness, Black and Hispanic patients were just 
as likely as Whites to achieve target lipid goals in this urban setting.
1030-186 The Detection of a Left Atrial Thrombus at 
Echocardiography is Associated with a Worse Outcome 
Compared to Patients with a Left Ventricular Thrombus
Karlheinz Seidl, Elke Fromm, Thorsten Becker, Klaus Dönges, Thomas Kleemann, Ömer 
Yildiz, Jochen Senges, Heart Center, Ludwigshafen, Germany
Aim of the study was to evaluate the long-term outcome in patients (pts) in whom a left 
atrial (LA) thrombus was detected during baseline echocardiographic study in comparison 
to pts, in whom a left ventricular (LV) thrombus was detected.
Methods: Since 1998, consecutively performed echocardiographic studies revealed an 
intracardiac thrombus in 321 pts (LA thrombus in 97 pts, LV thrombus in 224 pts).
Results: In 88 pts (89%) the LA thrombus was located in the left atrial appendage, 34 
LA-thrombi (35%) were ﬂoating. The location of the LV thrombi were in the LV-aneurysm 
in 207 pts (92%). Only 16 LV-thrombi (7%) were ﬂoating. Oral anticoagulation (OAC) with 
warfarin during FU was administered in 90% of pts with LA thrombus compared to 61% 
of pts with LV thrombus (p=0.002). Overall 66 % of pts with OAC were in the target range 
of INR 2-3 at the end of follow up (FU). Long-term outcome during mean FU of 31 ± 17 
months is shown in the table. In multivariate analysis the presence of a LA thrombus 
(QR 2.8, CI 1.04-7.08) was independently associated with a risk for thromboembolic 
complications during FU.
Conclusion: Pts with LA thrombus have a higher mortality, more thromboembolic 
complications and more often cerebral bleedings compared to pts with LV thrombus. The 
risk of ischemic stroke is 2.5 times higher in pts with LA thrombus compared to pts with 
LV thrombus.
LV thrombus/LA thrombus (* p < 0.05) 
LV thrombus 224 pts LA thrombus 97 pts
death 28 (12.5%) 15 (15%)*
ischemic stroke 11 (5%) 12 (13%)*
peripheral embolism 5 (2.2%) 1 (1%)
cerebral bleeding - 3 (3%)
1030-187 NT-pro BNP and C-Reactive Protein as Predictors of 
Major Adverse Cardiovascular Events (MACEs) and 
Target Vessel Revascularization (TVR) in Patients with 
Coronary Artery Disease (CAD)
Dao-Fu Dai, Jiunn-Lee Lin, Chih-Min Lin, Fu-Tien Chiang, Chuen-Den Tseng, Kwan-
Lih Hsu, Yung-Zu Tseng, Juey-Jen Hwang, National Taiwan University Hospital, Taipei, 
Taiwan,ROC, Taoyuan General Hospital, Taoyuan, Taiwan,ROC
The levels of NT-proBNP are elevated in heart failure and other triggers of ventricular 
dysfunction, such as myocardial ischemia. We recruited 424 patients with angiographically-
proven CAD. Cutoff values for plasma NT-proBNP and CRP are 682 pg/mL and 3.0mg/L, 
respectively. MACEs (CV mortality, MI and stroke) and TVR were recorded during the 
8-26 months follow-up.
Results: (ﬁgure). Cox regression showed the independent predictors for MACEs are: 
diabetes (HR:2.0, 95%CI: 1.0, 3.7), NT-proBNP (HR:5.4, 95% CI: 2.9, 10.0) and CRP 
(HR:2.1, 95%CI: 1.1, 4.1); for TVR: diabetes (HR:2.2, 95% CI:1.2,3.9), NT-proBNP 
(HR:3.0, 95% CI:1.8, 5.0) and CRP (HR:1.8, 95%CI:1.1, 2.8). 
Conclusion: The combination of plasma NT-proBNP and CRP is a strong predictor of 
MACEs and TVR in patients with coronary artery disease. 
1030-188 Incidence and Prognosis of Complete Left Bundle 
Branch Block: A Population-Based Study of Four 
Decades
Ryo Imanishi, Shinji Seto, Katsusuke Yano, Masazumi Akahoshi, Nagasaki University, 
Nagasaki, Japan, Radiation Effects Research Foundation, Nagasaki, Japan
Background: To assess the incidence and prognosis of CLBBB based on the longitudinal 
study in the general population.
Methods: We collected the incident CLBBB cases and vital status in 17,361 subjects 
(6,663 men, 10,698 women) who had undergone biennial examinations including blood 
sampling, electrocardiogram (ECG), blood pressure and cardiothoracic ratio (CTR) 
measurements since 1958 through 2003. One-hundred ten incident CLBBB cases (41 
men, 69 women) and 456 age-sex-matched control cases (100 men, 356 women) were 
selected. Cox proportional hazards model was used to compare all-cause and cause-
speciﬁc mortality of CLBBB cases with controls after adjusting for age, sex and basic 
diseases.
Results: The age at CLBBB appearance was 69.6 ± 10.0 years old in men and 68.3 
± 10.9 years old in women. The incidence of CLBBB increased with age: 1.9/100,000 
person-years at age <50, 18.3 in 50s, 42.4 in 60s, 66.2 in 70s, 157.3 at age ≥80 for 
men, and 2.2 at age <50, 21.7 in 50s, 35.6 in 60s, 62.7 in 70s, 113.5 at age ≥80 for 
women. As basic diseases, the rate of hypertension and ischemic heart disease was 
signiﬁcantly higher in CLBBB cases. ECG diagnosis before CLBBB showed the higher 
rate of left ventricular hypertrophy (LVH), ST-T change and poor R wave progression 
in CLBBB cases. CTR was not signiﬁcantly different before the appearance of CLBBB 
between cases and controls (48.9 ± 5.5% vs. 48.9 ± 5.0%, P = 0.985), but was so at 
the appearance of CLBBB (51.9 ± 6.1% vs. 50.3 ± 5.5%, P = 0.01). In Cox proportional 
hazard model, all cause mortality was similar between CLBBB cases and controls (58.2% 
vs. 53.9%, P = 0.381). However, the mortality of cardiac diseases including congestive 
heart failure and myocardial infarction was signiﬁcantly higher in CLBBB cases (42.2% 
vs. 18.3%, P = 0.0001).
Conclusion: The age at the appearance of CLBBB was relatively high, and the incidence 
of CLBBB dramatically increased with age in both sexes. Hypertension, ischemic heart 
disease, LVH, ST-T change and increased CTR were related to the appearance of 
CLBBB. CLBBB did not predict all-cause mortality but predicted cardiac disease mortality 
independently from age, sex and basic diseases.
1030-189 Impact Of Increasing Urbanization And Obesity On 
Absolute Cardiovascular Risk And Metabolic Syndrome 
in an Asian Indian Population
Vivek Chaturvedi, Dorairaj Prabhakaran, Pankaj Shah, Lakshmy Ramakrishnan, Bela 
Shah, K. Srinath Reddy, Initiative for Cardiovascular Health Research in the Developing 
Countries, New Delhi, India, All India Institute of Medical Sciences, New Delhi, India
Objective: The increasing burden of cardiovascular disease (CVD) in India has been 
attributed to increasing urbanization with acquisition of adverse lifestyles. However, data 
documenting this epidemiological transition are scarce. We investigated the impact of 
place of residence on absolute cardiovascular risk (as determined by Framingham risk 
equation, 1999) and metabolic syndrome in India.
Methods: We conducted a representative cross-sectional community-based study in 
and around Delhi, India in 4044 adults (35-64 years). CVD risk assessment was carried 
out in rural (n=1185), semi-urban or ‘resettlement’ areas (n=497), and urban residences 
(n=2362).
Results: The mean age of the population was ~46 years and 50% of respondents were 
women, in all the localities. The mean Framingham risk score increased with progressive 
urbanization (p for trend<0.001). The proportion of individuals with score deﬁning coronary 
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heart disease (CHD) risk more than 20% over 10 years (high-risk), was 5%, 7%, and 11% 
for men and 0.8%, 1.2% and 5% for women in rural, resettlement and urban population 
respectively ( chi-square for trend for both, p<0.001). Overall prevalence of metabolic 
syndrome was 12%, 20% and 36% in rural, resettlement and urban populations respectively 
(chi-square for trend, p<0.001, for both men and women). Overall prevalence of high-risk 
status by Framingham criteria was 17% in those with metabolic syndrome, irrespective of 
sex and locality. Probable CHD (by ECG and/or Rose’s angina questionnaire) was present 
in 22% of those with metabolic syndrome in urban areas (unadjusted OR 4.6, p<0.001). 
Prevalence of metabolic syndrome and CHD risk increased progressively with rising body 
mass-index (BMI). Non-rural residence signiﬁcantly elevated the risk of likelihood of CHD 
(OR for high-risk category 1.5 for resettlement and 2.6 for urban, p<0.001) and metabolic 
syndrome (OR 1.6 for resettlement and 2.0 for urban areas, p<0.01) even after adjusting 
for age, BMI, and sex.
Conclusion: The risk for CVD and metabolic syndrome increases progressively with 
degree of urbanization in India. Increasing obesity in urban areas is a major, but not only, 
determinant of this risk gradient.
1030-190 Burden, Rate of Screening and Awareness of 
Cardiovascular Risk Factors in a Geographically 
Limited Latin American Population
Francisco Lopez-Jimenez, Ector Jaime Ramirez-Barba, David Vega, Elia Lara, Virend 
K. Somers, Randal J. Thomas, Thomas E. Kottke, Mayo Clinic, Rochester, MN, Health 
Department, State of Guanajuato, Mexico, Guanajuato, Mexico
Background: Cardiovascular disease represents the number one cause of death in 
Mexico and many other countries in Latin America, but population-based data about the 
prevalence, level of awareness and knowledge of cardiovascular risk factors are lacking.
Methods This was a cross-sectional, population-based survey of cardiovascular disease 
risk factors in the state of Guanajuato, Mexico, where sociodemographic characteristics 
are similar to the national average. Samples were selected by a two-stage cluster design. 
Neighborhoods identiﬁed as basic geographical statistical units were randomly selected 
from urban and rural populations, weighted for the socioeconomic characteristics of 
the entire state. The face-to-face interviews were performed at participants’ home. 
Random blood glucose and total cholesterol measurements were performed using a 
semiquantitative analyzer using ﬁngertip blood sampling. Nutritional and physical activity 
data were assessed using standardized questionnaires.
Results: Of persons contacted, 99.5% agreed to participate. From the 3083 adults 
included, 52% resided in rural communities. Cardiovascular risk factors were highly 
prevalent; 67.2% had a BMI equal or greater than 25 kg/m2, while 50.3% of women had 
central obesity; 18.3% of participants had hypertension, 18.3% had hyperlipidemia, 
9.1% had diabetes mellitus, and 60% did not do any regular exercise; 27.3% of men 
reported current smoking. Regarding self-reported screening in the preceding 5 years, 
17.6% of people had not had a blood pressure check, 83.6% had not had tested their 
serum cholesterol and 43.1% had not had a blood glucose check. The immense majority 
of subjects identiﬁed at least four out of the ﬁve major modiﬁable cardiovascular risk 
factors: diabetes mellitus, hypertension, hyperlipidemia, obesity and smoking, out of a 
list of multiple factors.
Conclusions: There is a high prevalence of cardiovascular risk factors in Mexico with 
suboptimal screening for diabetes, and dyslipidemia. These ﬁndings conﬁrm the need 
for effective public health programs to decrease the current and increasing burden of 
cardiovascular disease in Latin America.
1030-191 Beyond LDL Control: Additional Beneﬁts of Better 
Control of Hypertension and Glycemia in Patients on 
Statin Therapy: An Analysis From PROVE IT-TIMI-22
Kausik K. Ray, Christopher P. Cannon, Richard Cairns, Stephen D. Wiviott, Ajay J. 
Kirtane, Marc S. Sabatine, Carolyn Hoss McCabe, Eugene Braunwald, C. Michael 
Gibson, Brigham and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background: The NCEP III guidelines now recommend an on treatment LDL of <70mg/
dl in high risk patients. We sought to evaluate whether ACS patients who fail to reach 
these NCEP targets might beneﬁt from other risk factor modiﬁcation (systolic blood 
pressure and glycemic control).
Methods: In PROVE IT-TIMI 22 patients free from clinical events at 4 months (n=3463) were 
evaluated for death, myocardial infarction (MI) or unstable angina (UA) to the end of follow 
up (mean 2 years). Systolic blood pressure, HBA1c and on treatment LDL were measured 
as part of the study protocol at 4 months. Target systolic blood pressure (JNC-7) was set at 
<140mm Hg and HBA1c ranges of <6, 6-7, >7 for glycemic control (as set by the ADA). 
Results: At 4 months a systolic blood pressure of <140mmHg was associated with a 2.3 
% lower rate of CV events in patients with LDL>=70mg/dl (HR 0.71 CI 0.52,0.97 p=0.03) 
and a 2.5 % lower rate in patients with LDLs <70mg/dl (HR 0.64 CI 0.41,1 p=0.05) (Figure 
1). HBA1c was only available in 2835 event free patients.Within LDL strata better glycemic 
control (<6%) tended to be associated with a reduction in CV events, which was most 
signiﬁcant at higher LDL levels (Figure 2) 
Conclusions: Achieving a target BP of <140mmHg and better glycemic control at 4 
months is associated with improved CV outcomes in ACS patients. BP lowering appeared 
to be equally important in both low and high LDL subgroups. The lowest event rates were 
in seen in those patients who achieved an LDL <70 mg/dl and a HBA1c <6.
1030-192 Coronary Heart Disease Events and Associated Costs 
in United States Adults With Uncontrolled Comorbid 
Hypertension and Dyslipidemia
Joshua S. Benner, Allison A. Petrilla, Timothy W. Smith, David Klingman, David S. 
Battleman, ValueMedics Research, LLC, Arlington, VA, Leonard Davis Institute of Health 
Economics, Philadelphia, PA
Background: Hypertension (HTN) and dyslipidemia (DYS) are prevalent risk factors for 
coronary heart disease (CHD) that often coexist. However, the clinical and economic burden 
of uncontrolled comorbid HTN/DYS has not been well studied. This study determined the 
prevalence of uncontrolled HTN/DYS, frequency of CHD events attributable to HTN/DYS, 
and associated medical costs.
Methods: Prevalence of HTN/DYS was calculated using patient-level data from the Third 
National Health and Nutrition Examination Survey (NHANES III). Patients with uncontrolled 
HTN/DYS were identiﬁed by comparing observed blood pressure (BP) and cholesterol 
levels with JNC VII and NCEP ATP III criteria, respectively. Framingham risk equations 
were used to calculate the 4-year risk of CHD; HTN and DYS were then statistically 
controlled and risks recalculated. The difference in the expected number of events among 
US adults was thus attributable to HTN/DYS. First-year direct medical costs of preventable 
events were calculated based on event-speciﬁc cost ﬁgures from the literature.
Results: 6,424 NHANES III subjects (representing 148 million non-institutionalized 
civilian US adults) were included in the study. The weighted prevalence of uncontrolled 
HTN/DYS was 17.9 million (12.1%) and nearly 2 in 3 US adults with HTN also have DYS. 
Mean age of patients with uncontrolled HTN/DYS was 61.8 (SE = 0.8) years; 61% were 
male. Mean 4-year risk of CHD was 9.8% among patients with uncontrolled HTN/DYS, 
versus 4.8% and 4.7% in patients with uncontrolled HTN alone or uncontrolled DYS alone, 
respectively, and 1.0% in patients with neither condition. Among those with uncontrolled 
HTN/DYS, 825,241 events (47% of expected events) could be prevented over 4 years if 
both conditions were controlled. The ﬁrst-year direct medical costs of these preventable 
events totaled $10.5 billion.
Conclusions: The clinical and economic burden of CHD is substantial in patients with 
uncontrolled comorbid HTN/DYS; 1 in 10 will experience a CHD event within 4 years. Nearly 
half of these events could be prevented by controlling BP and cholesterol. Intensive efforts 
are needed to screen and treat patients for multiple, modiﬁable cardiovascular risk factors.
POSTER SESSION
1031  Innovations in Computing and 
Cardiovascular Diagnosis
Sunday, March 06, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1031-181 Multichannel Magnetocardiographic Visualization 
of Myocardial Ischemia: Novel Noncontact Mapping 
Method
Hideaki Kanzaki, Satoshi Nakatani, Akihiko Kandori, Keiji Tsukada, Masafumi Kitakaze, 
Kunio Miyatake, National Cardiovascular Center, Osaka, Japan, Hitachi Central 
Research Laboratory, Tokyo, Japan
Background: Magnetocardiography (MCG) is a noncontact mapping technique to record 
the magnetic ﬁeld around the heart produced by cardiac electric activity. Our hypothesis 
is that multichannel MCG is useful for screening of myocardial ischemia.
Methods: The 64-channel MCG (Hitachi MC-6400) following the Master’s exercise test 
was performed in 29 patients: 17 with signiﬁcant angiographic stenosis and 12 without 
stenosis. Isomagnetic ﬁeld maps were constructed with the MCG signals at ST-segment 
to estimate depth of ischemic area using Biot-Savart Law.
Results: Exercise-induced abnormal current ﬂow was obtained around the left ventricle 
(Figure, Left) in 12 of 17 with stenosis (sensitivity 71%) and was not obtained in 12 of 12 
without stenosis (speciﬁcity 100%). The estimated depth was feasible in 10 (59%): 4.9 ± 
1.4 cm from the anterior chest wall in left anterior descending artery lesion and 7.4 ± 1.4 
cm in right coronary artery or left circumﬂex artery lesion. The abnormal current ﬂow was 
not provoked by exercise after coronary angioplasty (Figure, Right).
Conculsion: Multichannel MCG is a novel noncontact mapping method for visualization 
of myocardial ischemia. 
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1031-182  Classiﬁying Heart Valve Pathology Using Voice-
Recognition Technology
Marie A. Guion, Ahmed Tewﬁk, KP Madhu, Arthur Erdman, University of Minnesota, 
Minneapolis, MN
Background: Use of the stethoscope--one of the oldest tools in cardiology--is fast, 
inexpensive, and minimally invasive, but interpreting the information it yields can be highly 
complex. Advanced digital signal processing software has the potential to revolutionize the 
stethoscope through the use of mathematical algorithms to interpret acoustic information. 
In this study, a novel classiﬁcation algorithm based on voice-recognition systems is used 
for identifying differences between normal and diseased heart sounds.
Methods: 160 random patients undergoing a trans-thoracic echocardiogram were 
recruited from the Fairview University Hospital in Minneapolis, Minnesota. Patient data 
was collected using an electronic stethoscope (20-1000 Hz) and echo reports were 
used to classify valves as normal or diseased. 60 patients deﬁned training spaces for the 
apex, aortic and tricuspid sites. Classiﬁcation of sound signals was performed by linearly 
combining the mel-cepstrum and Principal Components Analysis feature vectors. During 
the training phase, patient data associated with normal and diseased valves was used 
to obtain a representative vector of each class. During the recognition phase, the feature 
vector from the test patient was compared with representative vectors.
Results: The classiﬁcation accuracy of diseased patients was approximately 75% on 
the validation set comprised of 100 patients (71 diseased, 29 normal). There were 8 
false negatives and 15 false positives. The algorithm sensitivity is 88.7% and speciﬁcity 
is 48.3%.
Conclusion: Voice recognition technology can be used to analyze the sounds produced 
by heart valves to assist a physician in determining whether a patient should be referred 
for an echocardiogram. Because voice recognition technology was developed as a 
generic signal processing method to recognize a large vocabulary of words (i.e., speciﬁc 
acoustic patterns) from a variety of speakers, this method has signiﬁcant potential to help 
cardiologists to classify and recognize speciﬁc “acoustic signatures” associated with a 
wide range of cardiac events and conditions.
1031-193 Assessment Of Coronary Flow Reserve By New Indices 
Extracted From Semi-Automated Doppler Tracing
Enrico G. Caiani, Luigi Delﬁno, Valentina Magagnin, Christine Champlon, Massimo 
Llambro, Sergio Cerutti, Maurizio Turiel, Politecnico di Milano, Milano, Italy, Istituto 
Ortopedico Galeazzi, Università degli Studi di Milano, Milano, Italy
Background. Transthoracic Doppler echocardiography provides a noninvasive evaluation 
of coronary ﬂow velocity reserve (CFR) in the distal LAD, as the ratio of maximal 
(pharmacologically stimulated) to baseline diastolic velocity peak, manually obtained from 
Doppler tracings. While CFR>2.5 is associated with normality and CFR<1.9 with reduced 
ﬂow, the interpretation of 1.9<CFR<2.5 is still unclear.
Our goals were: 1) to develop a technique for semi-automated Doppler tracing and 
computation of other indices than CFR; 2) to test if any of these indices could reﬂect 
reduced coronary ﬂow.
Methods. 15 normal (N) subjects and 15 patients (P) with reduced LAD ﬂow, conﬁrmed 
by invasive techniques, were studied for CFR evaluation. Stress echo (Philips Sonos 
5500, S8 probe) was performed with dipyridamole (0.56 mg/kg over 4 min + 0.28 mg/kg 
over 2 min). Custom software was used to detect the Doppler proﬁle and compute CFR, 
systolic (S) and diastolic (D) peak and mean velocity, S and D phase durations, D positive 
and negative maximum ﬁrst derivative, D to S peak velocity ratio (DSVR).
Results. The proposed method correctly extracted the Doppler proﬁle, as conﬁrmed by 
visual inspection. The CFR (mean±SD) was greater in N (3.1±0.6) than in P (1.4±0.4). In 
addition, many of the new indices (Table) evidenced signiﬁcant differences (#) between 
the two groups.
Conclusions. In addition to CFR, computerized analysis of Doppler coronary ﬂow velocity 
could provide new indices useful for clinical evaluation.
 
1031-194 Decrease in R-R Interval Entropy Prior to the Onset of 
Atrial Fibrillation
Volkan Tuzcu, Selman Nas, Tulay Borklu, Ahmet Ugur, Cincinnati Children`s Hospital, 
University of Cincinnati, Cincinnati, OH, Arkansas Children`s Hospital, University of 
Arkansas, Little Rock, AR
Background. It has been proposed that autonomic nervous system might have a role in 
the initiation of atrial ﬁbrillation (AF). We studied the R-R interval entropy changes prior to 
the onset of AF using sample entropy.
Methods. We included 25 patients with lone AF for our study. Each record set contains 
two 30-minute records from 25 subjects. Each patient has of 30-minute records containing 
the ECG immediately preceding an episode of AF (pre-AF) along with the ECG containing 
30 minutes of the ECG during a period that is distant from any episode of AF (AFd). 
Sample entropy was used for entropy analysis.
Results. The sample entropy of R-R intervals was found to be signiﬁcantly reduced in 
the pre-AF period compared to the AFd period (0.45 + 0.25 vs. 0.78 + 46, p = 0.003). We 
divided the pre-AF periods into three successive 10-minute segments and analyzed with 
sample entropy in order to show the presence of a possible trend. There was a signiﬁcant 
decreasing trend in entropy towards the onset of AF with linear mixed models (p = 0.002).
Conclusions. There is reduced heart rate complexity with a signiﬁcant decreasing trend 
in R-R interval entropy prior to the onset of AF. There is a need for well deﬁned studies 
with larger patient groups in order to assess the entropy changes further and to look for 
possible changes which might be predictor of impending AF episodes.
POSTER SESSION
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1057-181 Trends in Incidence of Atrial Fibrillation in Olmsted 
County, MN (1980-2000)
Yoko Miyasaka, Marion E. Barnes, Stephen S. Cha, Bernard J. Gersh, James B. Seward, 
Walter P. Abhayaratna, Kent R. Bailey, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: There is evidence that the prevalence of atrial ﬁbrillation (AF) increased during 
1968-1989. However, more contemporary trends in incidence of AF are not available.
Methods: The complete medical records for residents of Olmsted County, MN, who had an ECG-
conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were comprehensively reviewed for each 
incident AF case. The trends in overall incidence were evaluated. Incidence was calculated as the 
number of new AF cases in each year divided by the sum of the Olmsted County population in that 
year. Statistical comparison across time and between genders was via Poisson regression using 
PROC GENMOD in SAS, using a log link function, and log (population) offset.
Results: 4,618 residents (mean age 73 + 14 years, range 18 to 107 years; 51%men) 
were conﬁrmed to have developed incident AF between 1980-2000. The incidence rate 
was 3.1/1000 person-years in men and 2.7/1000 person-years in women. Adjusted for 
age, the incidence ratio for men and women was 1.86 (P<0.0001). The overall rate of 
increase in incidence of AF for the period of 1980-2000 was 0.62% per year (P=0.012). 
The yearly increase was 0.7% in men (p=0.04) and 0.54% in women (p=0.13), and was 
not signiﬁcantly different between men and women.
Conclusions: The overall age-adjusted incidence of AF increased signiﬁcantly for the period 
1980-2000. The rate of increase did not differ signiﬁcantly between men and women.
1057-182 Accuracy of Electrocardiogram Overreading by a 
Cardiologist in the Setting ofIncorrect Computer 
Interpretation
Daejoon Anh, Subramaniam Krishnan, Frank Bogun, Henry Ford Hospital, Detroit, MI, 
University of Michigan, Ann Arbor, MI
Background: Misdiagnoses of atrial ﬁbrillation(AF) based on misinterpretation of 
ECGs are common. The purpose of this study is to determine whether the specialty of 
the reading physician is associated with different accuracy in diagnosing ECGs initially 
misinterpreted as AF.
Methods: We retrieved 2,298 ECGs with the computerized interpretation of AF from 
1,085 patients. Two electrophysiologists identiﬁed 442 ECGs from 382 patients that 
were incorrectly interpreted as AF. Medical records of these patients were reviewed 
to determine 1) the specialty of the physician who ordered and initially interpreted the 
ECG (primary reader), 2) the accuracy of the interpretation by the primary reader, 3) the 
accuracy of the interpretation by the over-reading cardiologist.
Results: 
Specialty Interpretation corrected
Interpretation 
uncorrected Accuracy
Internist 93 38 71%
Emergency physician 105 35 75%
Other specialist † 20 14 59%
Cardiologist as primary reader 72 5 94% *
Cardiologist as over-reader 208 84 71% **
† Included surgeons, family practitioners, neurologists and anesthesiologists.
* P<0.05 vs. internist, emergency physician or other specialist.
* P<0.05 vs. cardiologist as primary reader.
2005_8_SpecialTopics.indd   333 12/23/04   10:13:30 AM
334A ABSTRACTS - Special Topics JACC February 1, 2005
S
pe
ci
al
 T
op
ic
s
Conclusion: ECGs incorrectly interpreted as AF by the computer algorithm was more often 
corrected by a cardiologist as compared to other specialists. Surprisingly, the interpretation 
of a cardiologist as a primary reader was more accurate than interpretation of a cardiologist 
as an overreader. Familiarity with an individual patient on whom an ECG is ordered and time 
constraints in the overreading process might account for this discrepancy. The overreading 
process of ECGs should take these limitations into account.
1057-185 Pharmacological Therapy Following First Atrial 
Fibrillation: Data from Two Decades (1980-2000)
Yoko Miyasaka, Marion E. Barnes, Stephen S. Cha, Kent R. Bailey, James B. Seward, 
Walter P. Abhayaratna, Bernard J. Gersh, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: The management of atrial ﬁbrillation (AF) has changed over time. We 
examined the pharmacotherapy used within 1 year of ﬁrst AF diagnosis.
Methods: The complete medical records for residents of Olmsted County, MN, who had 
an ECG-conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were reviewed. Use 
of rate control (beta-blocker, calcium channel blocker, and digoxin) and rhythm control 
(Class I and III antiarrhythmic drugs) medications was reviewed.
Results: A total of 4,618 residents (mean age 73 + 14 years, 51% men) developed 
incident AF. There were no changes in the overall use of rate control medications (Table). 
Speciﬁcally, beta-blocker and calcium channel blocker use increased signiﬁcantly, while 
digoxin use decreased signiﬁcantly. The overall use of rhythm control medications 
increased by almost 2 fold, largely due to increased use of class III antiarrhythmic drugs. 
The pattern of use of various types of medications following AF diagnosis, stratiﬁed by 
time periods, is detailed in Table. In a separate analysis, we have demonstrated that the 
overall mortality of AF patients did not change over the same time period.
Conclusions: Although the pharmacotherapy in AF patients changed considerably over the 2 
decades, the mortality risk of AF has remained unchanged. This is consistent with randomized 
trials demonstrating no mortality difference between rate and rhythm control strategies.
 
Table. Medication use in year 1 following AF diagnosis,  
stratiﬁed by time period 
1980-1984 1985-1990 1991-1994 1995-2000 TrendP value
Rate control medications
Beta blocker (%) 12 13 17 33 P<0.0001
Calcium channel blocker (%) 8 17 26 28 P<0.0001
Digoxin (%) 62 54 49 34 P<0.0001
Any rate control (%) 71 70 71 70 P=0.914
Rhythm control medication
Class I antiarrhythmics(%) 5.2 4.7 5.0 5.9 P=0.316
Class III antiarrhythmics (%) 0.6 0.5 2.0 5.3 P<0.0001
Any rhythm control (%) 5.8 5.2 7.0 11.2 P<0.0001
1057-186 Quality of Anticoagulation Control Among Patients With 
Atrial Fibrillation in Routine Medical Practice
Luke Boulanger, Jennifer Kim, Mark Friedman, Ole Hauch, Joseph Menzin, Boston 
Health Economics, Inc., Waltham, MA, Astra Zeneca, LP, Wilmington, DE
BACKGROUND: Patients with chronic non-valvular atrial ﬁbrillation (CNVAF) treated with 
warfarin in clinical trials and specialized clinic settings achieve a high percentage of time 
in therapeutic PT/INR range. This percent time in therapeutic PT/INR range is believed 
to be lower in routine medical practice, although most retrospective studies have been 
based on few patients/centers. In this study, we evaluate the quality of anticoagulation 
control in a large geographically diverse database of medical records.
METHODS: We employed a retrospective cohort design using electronic medical records 
data on 14,000+ patients with AF treated in US primary care settings. Patient selection 
criteria included: diagnosis of AF; age ≥ 40 years; current use of warfarin; results of 
≥ 2 PT/INR tests; and no indication of valvular disease, transient perioperative AF, or 
hyperthyroidism. The main study outcome was the percent of time patients spent in the 
recommended PT/INR range (2.0 - 3.0), calculated via the Rosendaal method.
RESULTS: A total of 6,454 patients met selection criteria. Their average age was 69 years 
and 41% were female. Estimated prevalence of hypertension was 56%, 25% had diabetes, 
22% had CHF, 15% had prior stroke, and 6% had prior MI. Patients spent 48% (95% CI: 
47 - 49%) of the time within recommended PT/INR range, 38% of the time below range, 
and 14% of the time above range; 27% had at least one PT/INR value above 5.0. Patients 
receiving care in the Midwest and West spent a larger percentage of time in the recommended 
range (54% and 51%, respectively) versus those in the South or Northeast (45% and 42%, 
respectively). Increased stroke risk (measured by the CHADS2 score) was associated with 
poorer anticoagulation control, while male sex was associated with more time in range.
CONCLUSION: Patients with CNVAF managed in primary care settings spend a substantial 
proportion of time out of therapeutic PT/INR range, especially below the recommended 
target, compared with results reported in studies of patients in specialized anticoagulation 
clinics or randomized clinical trials. The degree of anticoagulation control observed in this 
study is comparable to that noted in other studies based in primary care settings.
1057-187 Warfarin Candidacy and Prescription Among Elderly 
Patients Hospitalized With Atrial Fibrillation
J. D’Antonio, S. Regan, C. Evans-Molina, C. Shea, LE Henault, EM Hylek, 
Massachusetts General Hospital, Boston, MA
Background: Warfarin is effective in preventing stroke in atrial ﬁbrillation (AF). 
Studies from population databases cite warfarin underuse, questioning quality of care. 
Assessment of patient candidacy at treatment initiation would better deﬁne eligibility in 
real-world practice.
Methods: Patients with AF admitted to the medical service of an academic center 
were prospectively identiﬁed. Eligible patients were > 65 yrs, ECG veriﬁed AF, not on 
warfarin, and had longitudinal care in our clinics. Transient AF, AF post-cardiac surgery or 
coincident with an embolus was ineligible. Baseline data and discharge antithrombotics 
were extracted from medical records. Reason for not prescribing warfarin was obtained 
from the treating physician.
Results: We enrolled 426 patients from 2001 to 2003; 21 died before discharge. Of 405 
patients, 51% were >80 yrs, 75% had HTN, 36% heart failure, 8% prior stroke. Overall, 
51% were discharged on warfarin: 75% of those 65-69 yrs, 59% 70-79, 45% 80-89, and 
24% age >90. Independent predictors of warfarin non-use include: age per decade(OR 
1.5, 95% CI 1.1-2.1), falls(OR 4.7,2.1-10.7), prior bleed(OR 3.1,1.8-5.4), dementia(OR 
6.4,2.7-14.8), active malignancy(OR 4.6,1.8-11.7). Contraindications existed for nearly all 
(Table) including 30 patients (15%) who failed prior warfarin use.
Conclusion. Contraindications to warfarin were present for ~60% of patients > 80 yrs with 
AF. Alternative strategies for stroke prevention are needed in this vulnerable population.
Warfarin Non-Use Based on Age and Contraindication 
Overall < 80 Years > 80 Years
n=200 n=76 n=124
Bleeding Complications
Recurrent / Current (n=48)
Past History (n=8 ICH, n=11 other)
34% (67) 42%(32) 28% (35)
Recurrent Falls 32% (64) 20%(15) 40% (49)
Non-Adherence / Refusal 16% (33) 17% (13) 16% (20)
Comfort care 7% (13) 5% (4) 7% (9)
Other (e.g., labile HTN, alcohol abuse) 11% (23) 16% (12) 9% (11)
1057-188 Pharmacogenetic Dosing Algorithm based on CYP2C9 
Genotypes for the Quantitative Determination of Initial 
Warfarin Dose and Dose Adjustments
Benjamin D. Horne, John F. Carlquist, Joseph B. Muhlestein, Donald L. Lappé, Brent C. 
James, Dale G. Renlund, Jessica L. Clarke, Johnny E. Walker, Robert R. Pearson, Heath 
U. Jones, Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, University of Utah, Salt 
Lake City, UT
Background: While warfarin anticoagulation is used in a variety of cardiovascular 
conditions, individual therapy is sensitive to a multiplicity of variables making it difﬁcult 
to establish and maintain a therapeutic protime international normalized ratio (INR). We 
and others have shown that patient response to warfarin is, in part, determined by genetic 
variations within the CYP2C9 gene. Because genotype is the dominant determinant of 
dose, we developed a pharmacogenetic warfarin dosing algorithm.
Methods: Atrial ﬁbrillation patients (N=202) genotyped for the CYP2C9 *2 (C/T) and *3 
(A/C) single nucleotide polymorphisms (SNPs) and with data on age, sex, and weight 
were evaluated for prediction of stable warfarin dose (>1 month on same dose and INR 2-
3) by modeling in linear regression. Recursive partitioning determined dose thresholds for 
age and weight. Regression β-coefﬁcients were calculated from the natural log of warfarin 
dose for use in dose prediction.
Results: Regression coefﬁcients for the dose prediction model were as follows: for the 4 
observed genotypes: 0.00 (CCAA), -0.17 (CTAA), -0.35 (CCAC), and -1.64 (CTAC); for 
age: 0.20 (≤50 years), 0.00 (51-75 years), and -0.17 (>75 years); for weight: -0.15 (≤75 
kg), -0.07 (76-100 kg), 0.00 (101-110 kg), and 0.05 (>110 kg); for sex: 0.00 (female) and 
0.10 (male); and a constant of 3.56. The model accounted for 29% of the variation in 
patient warfarin dose, compared to 13% with only age, sex, and weight. Stable weekly 
doses ranged from 5.0-70.0 mg/week; the correlation with predicted dose was r=0.54 
(p<0.001). Predicted doses were categorized into groups to the nearest 3.5 mg/week, and 
ranged from 7.0-49.0 mg/week. The model was then integrated into a dose initialization 
and adjustment algorithm.
Conclusions: A quantitative warfarin dosing algorithm that incorporates CYP2C9 
genotype and other recognized factors (i.e., age, sex, weight) provides the best 
description of INR dose-variation to date and can easily be computed. This quantitative 
pharmacogenetic-based dosing algorithm is now available to be prospectively tested 
in a randomized clinical trial to improve safety and efﬁciency of warfarin initiation and 
maintenance therapy.
1057-189 Is Opthalmic Screening Necessary for Amiodarone-
Treated Patients?
Rod S. Passman, Veerpal Singh, Rahmi Kapur, Rishi Sharma, Charles L. Bennett, 
Northwestern University, Chicago, IL
Background: Amiodarone is the most widely prescribed antiarrhythmic drug. Reports of 
blindness from amiodarone-associated optic neuropathy/neuritis (AON) have prompted 
recommendations for regular ophthalmic exams, though no established causal relationship 
exists. Investigators with Research on Adverse Drug Events & Reports (RADAR) sought 
to critically evaluate adverse event report information supporting this guideline.
Methods: Comparisons of quality and completeness of AON reports were evaluated 
using reports by Food & Drug Administration (FDA) from pharmaceutical suppliers 
(n=185) or from health professionals (n=29), case reports (n=25), and clinical trial toxicity 
reports (n=23). Permanent blindness rates were derived using World Health Organization 
& US Public Health Services (USPHS) deﬁnitions.
Results: There were 262 cases of AON. Completeness and diagnostic certainty were poor 
for reports submitted to the FDA and best for case reports & clinical trial reports (p<0.01). 
In persons with AON in published reports, the permanent blindness rate was 8.3% (WHO 
deﬁnition) and 12.5% (USPHS deﬁnition). No data were available on AON rates.
Conclusion: Support for routine ophthalmic exams for patients on amiodarone is 
limited. Case reports & clinical trial reports provided more complete information than 
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those reported to the FDA. A prospective registry is needed to assess the incidence and 
clinical course of AON, the results of which may be used to support better screening 
recommendations.
 
1057-190 Warfarin Utilization and Stroke Risk in Patients With 
Chronic Non-Valvular Atrial Fibrillation
Stephen J. Boccuzzi, Judith J. Stephenson, Charles A. Kreilick, Jane F. Beaulieu, Ole 
Hauch, Jennifer Kim, Aetna Health Information Solutions, Blue Bell, PA, AstraZeneca LP, 
Wilmington, DE
BACKGROUND: Atrial ﬁbrillation (AF), a common arrhythmia, is associated with a 5-fold 
increase in risk of stroke. Clinical trials have shown long-term anticoagulation therapy 
substantially reduces risk of stroke. However, literature indicates that anticoagulation 
therapy is sub-optimally managed in clinical practice. This study characterized the real world 
effectiveness of warfarin therapy in chronic non-valvular atrial ﬁbrillation (CNVAF) patients.
METHODS: This retrospective, observational cohort analysis utilized medical and 
pharmacy claims and laboratory data from a large, geographically diverse managed 
care organization to identify a CNVAF incidence cohort between 1/1/01 - 6/30/02. 
Continuously enrolled, beneﬁt-eligible members with no evidence of AF (ICD9 = 427.31) 
or warfarin claims 12 months prior to AF diagnosis were followed for > 6 months to the 
common termination point, 12/31/02. Cardiovascular (CV) outcomes evaluated were: TIA, 
ischemic stroke and major bleed. Warfarin exposure was determined by days supply per 
prescription and the timing of intervening INR tests. Percent time in INR therapeutic range 
was determined for members with INR test results. Cox proportional hazard models were 
used to assess the association between warfarin exposure and risk of ischemic stroke 
and other CV outcomes.
RESULTS: Of 3,891 CNVAF patients, 45% were aged 45-64 years and 55% were > 65 
years; 62% were male. Associated stroke risk factors were: hypertension, 52%; age > 
75, 32%; diabetes, 18%; CHF, 16%; history of stroke/TIA, 5%. First CV outcome rates 
were: TIA 2%; ischemic stroke, 5%; major bleed, 8%. After adjusting for potential clinical 
and demographic confounding factors, warfarin exposure was associated with a 19% 
decrease in the risk of ischemic stroke (HR 0.81; 95% CI 0.57-1.16). Patients exposed to 
warfarin were within therapeutic range only 48% of the time.
CONCLUSIONS: Warfarin exposure at the time of the event appears to be associated 
with only a modest decrease in risk of stroke. The observed gap between effectiveness of 
warfarin in routine medical care and effectiveness reported in clinical trials may be due to 
difﬁculties in maintaining patients within the therapeutic range.
1057-191 Silent Atrial Fibrillation in Olmsted County, MN  
(1980-2000): Risk and Prognosis
Marion E. Barnes, Yoko Miyasaka, Stephen S. Cha, Bernard J. Gersh, James B. Seward, 
Walter P. Abhayaratna, Kent R. Bailey, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: There is a paucity of data on silent atrial ﬁbrillation (AF). We aimed to 
estimate its prevalence, and determine the associated clinical proﬁle and prognosis.
Methods: Medical records for all adult residents of Olmsted County, MN, with an ECG-
conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were comprehensively reviewed. 
Symptoms present at AF detection were classiﬁed as typical of AF; nonspeciﬁc; silent 
(asymptomatic, AF detected incidentally); and unclassiﬁable. The clinical proﬁle and 
survival of patients who had silent AF versus those with symptoms were compared.
Results:  A total of 4618 Olmsted County residents (mean age 73 ± 14 years, range 
18 to 107 years; 51% men) had ﬁrst AF identiﬁed. Of these 20% (n=916) were silent, 
35% (n=1599) were associated with nonspeciﬁc symptoms, and 18% (n=816) with typical 
AF symptoms. Excluded from this analysis were 1287 patients (28%) with unclassiﬁable 
symptoms. In a multivariate model, risk for silent AF was positively associated with older 
age, higher diastolic blood pressure, and slower heart rate. The overall age-adjusted 
survival of the silent AF group did not differ from those with symptoms, irrespective of 
whether patients with history of myocardial infarction (MI) or congestive heart failure 
(CHF) were excluded.
Conclusion:  Silent AF accounts for a signiﬁcant proportion of the total AF burden. In 
this study, the baseline characteristics of patients with silent AF differed from those with 
symptoms, but survival was not different.
 
Table 1 
Variable Odds Ratio Lower 95% CI Upper 95% CI P-value
Age 1.031 1.024 1.038 <0.0001
Diastolic blood pressure 1.017 1.011 1.024 <0.0001
Heart rate at AF 0.982 0.979 0.985 <0.0001
History of MI 0.347 0.273 0.442 <0.0001
History of CHF 0.454 0.358 0.576 <0.0001
History of valvular heart disease 0.723 0.591 0.884 0.0016
History of COPD 0.669 0.539 0.832 0.0003
1057-192 Trends of Overall and Sex-Speciﬁc Mortality Risks After 
First Atrial Fibrillation in Olmsted County, MN (1980-
2000)
Yoko Miyasaka, Marion E. Barnes, Stephen S. Cha, Bernard J. Gersh, James B. Seward, 
Walter P. Abhayaratna, Kent R. Bailey, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: Increasing trends of atrial ﬁbrillation (AF) prevalence between 1968-1989 
have been shown. However, risk factors and trends of mortality risk following AF are 
poorly understood.
Methods: The complete medical records for residents of Olmsted County, MN, who had 
an ECG-conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were comprehensively 
reviewed for each incident AF case. Death was conﬁrmed from review of death certiﬁcate 
and/or Social Security Death Index. Survival was compared with expected based on 
life tables for the Minnesota white population, both overall, and separately by gender. 
Because of the high early mortality, this comparison with expected survival was also done 
separately for year 1 and for subsequent years after AF diagnosis. Trends in survival were 
determined using Cox proportional hazards analyses.
Results: A total of 4,618 residents (mean age 73 ± 14 years, range 18 to 107 years; 
51% men) were conﬁrmed to have developed incident AF between 1980-2000. Over a 
mean follow-up time of 5.3 ± 5.0 years, 3085 (67%) died, 1052 (23%) in year 1 and 2033 
(44%) in subsequent years. Compared to the general population of similar age, there was 
a signiﬁcantly increased mortality risk (P<0.0001), with excess risk most pronounced in 
year 1 (1052 observed versus 220.4 expected, HR 4.77), but present also in later follow-
up (2033 observed versus 1262 expected, HR = 1.61). When analyzed separately by 
gender, the corresponding HRs were 4.92 and 1.55 (men) and 4.64 and 1.67 (women). 
In Cox analysis, survival was strongly related to age and male gender, but not calendar 
year of incident AF.
Conclusions: Overall and sex-speciﬁc mortality following incident AF was greatly in 
excess of expected, particularly in year 1. The relative mortality excess was similar for 
men and women. The mortality risk did not change over the period 1980-2000.
1057-193 Impact of New-Onset Atrial Fibrillation on In-Hospital 
Outcomes Following Cardiac Surgery
Imtiaz Ali, Karen Buth, Dalhousie University, Halifax, NS, Canada
Background: It is unknown whether new-onset atrial ﬁbrillation (AF) leads to increased 
operative mortality. We sought to determine if AF is associated with increased in-hospital 
mortality (IHM) following cardiac surgery.
Methods: Patients in sinus rhythm having isolated coronary artery bypass (CABG) and 
CABG+valve surgery were identiﬁed (n=7347).A logistic regression model determined 
the association of AF with IHM.Propensity scores were used to match two subgroups of 
patients(GrpI, no AF, n=2015; GrpII, AF, n=2015)on multiple factors.Outcomes assessed 
were IHM, stroke, perioperative myocardial infarction (MI), intra-aortic balloon pump use 
(IABP), gastrointestinal complications(GI comp), mediastinitis(MED), septicemia(SEP), 
and postoperative renal failure(RF).
Results: Of the 7347 patients,2047(28%) developed AF and 5300(72%) did not. AF 
patients were more likely to be >70 yrs age, having CABG+valve, hypertensive, have 
peripheral and cerebrovascular disease, chronic obstructive pulmonary disease( 
p=0.0001), EF<40%(p=0.005), MI<7days(p=0.004), and preoperative IABP(p=0.004).
Unadjusted rates of stroke(2.8%vs.1.2%), GI comp (4.4%vs.1.7%), MED(1.3%vs.0.4%), 
SEP(4%vs.0.9%), and RF(7.8%vs.2.9%) were signiﬁcantly higher (p=0.0001) in 
patients with AF. After adjustment, AF was not an independent predictor of IHM 
(OR=0.8,95%CI=0.6-1.2,p=0.3).Of the 2047 patients who developed AF, 2015(98%) were 
matched 1:1 with 2015 of the 5300 patients who did not develop AF. Propensity-adjusted 
results revealed no difference in IHM (GrpI, 3.5%;GrpII, 2.9%,p=0.28). However, stroke
(2.8%vs1.6%,p=0.007), GI comp(4.2%vs2.1%,p=0.0002), MED(1.3%vs0.4%,p=0.0013), 
SEP(4%vs1.1%,p=0.0001), and RF(7.6%vs4.3%,p=0.0001) were increased in patients 
who developed AF.
Conclusions:  AF following cardiac surgery is not associated with increased in-hospital 
mortality. However, this complication is independently associated with increased rates of 
stroke, GI comp, MED, SEP, and RF.
1057-194 Economic Impact of Reduced Incidence of Atrial 
Fibrillation in Patients With Left Ventricular Dysfunction 
Treated With Enalapril
Monika Wagner, Donna Rindress, Brigitte Desjardins, Anique Ducharme, Jean Claude 
Tardif, BioMedCom Consultants, Inc., Montreal, PQ, Canada, Montreal Heart Institute, 
Montreal, PQ, Canada
Background: Atrial ﬁbrillation (AF) in the setting of heart failure (HF) is linked to embolic 
stroke and exacerbation of HF. The rate of new-onset AF in a subset of patients with left 
ventricular dysfunction and mild to moderate HF enrolled in the Studies of Left Ventricular 
Dysfunction (SoLVD) trials was signiﬁcantly lower with enalapril than with placebo (5.4% 
vs 24% over 2.9 years; P<.0001). The objective of this study was to predict economic 
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beneﬁts over ﬁve and ten years of reduced AF incidence in patients receiving enalapril for 
the treatment of HF from a Canadian Ministry of Health perspective.
Methods: The costs and consequences of AF prevention with enalapril were modeled 
over ﬁve or ten years using a Markov decision analytical model. Patients were assigned 
to one of four health states: “no AF”, “AF”, “post-stroke”, and “death” and moved from one 
state to the other according to published incidence rates. The model considered increased 
incidence of stroke as the main consequence of AF and assumed that most patients 
developing AF would receive warfarin treatment for stroke prevention. Resource utilization 
and costs were mostly retrieved from published Canadian studies.
Results: Reduced incidence of AF with enalapril resulted in savings of $382 and $525 
per patient over ﬁve and ten years, respectively. These savings stemmed from reduced 
hospitalization for AF, and less need for warfarin and amiodarone therapy, which were direct 
consequences of the lower incidence of AF in patients receiving enalapril. Sensitivity analyses 
demonstrated that enalapril becomes more cost-saving as the baseline risk of embolic stroke 
in patients with AF increases and as the use of warfarin prophylaxis decreases.
Conclusion: AF prevention with enalapril leads to both clinical and economic advantages, 
in addition to its already well-established beneﬁts of reduced morbidity, mortality, and 
costs in patients with HF.
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1086-189 Decision Making Characteristics and Preferences in 
Acute Myocardial Infarction Patients: Insights from 
PREMIER
Carole J. Decker, Nina Worden, Karen Nugent, Kimberly Reid, Harlan Krumholz, Judith 
Lichtman, Eric Peterson, John Spertus, Mid America Heart Institute, Kansas City, MO, 
University of Missouri - Kansas City, Kansas City, MO
Background: The Institute of Medicine has challenged medicine to evolve care delivery 
so patients assume an active role in medical decision-making (MDM). The preference of 
patients for this more active role may vary in different clinical situations. We examined 
the frequency and characteristics with which myocardial infarction (MI) patients wish to 
assume an active role in MDM about their treatment.
Methods: 2,502 MI patients were prospectively enrolled at 19 centers in PREMIER, an 
observational MI registry. We evaluated patients’ MDM preferences using a validated tool 
to quantify preferences by patients based on the following decision-making categories: 
“doctor alone”, “mostly doctor”, “share equally”, “mostly patient (self)”, and “patient (self) 
alone”. An active role was deﬁned as “mostly self”, “self alone” and “shared equally”. We 
examined demographic, clinical, and baseline health status data as they related to active 
MDM preferences using a multivariable logistic regression model.
Results: Overall, 69% of MI patients (n=1682/2448) desired an active role in making 
decisions. Multivariable model results identiﬁed that the typical patient who wishes to have 
an active role in decision-making is: younger (Odds Ratio 0.8 per 10 years, 95% CI 0.72 
to 0.83, p<0.0001); more likely to be female (OR 1.6, 95% CI 1.33 to 1.99, p<0.0001); 
white (OR 1.5, 95% CI 1.19 to 1.90, p=0.0007); college educated (OR 1.9, 95% CI 1.56 to 
2.28, p<0.0001); non-diabetic (OR 1.4, 95% CI 1.11 to 1.67, p=0.003); and more likely to 
live on the West Coast as opposed to the Midwest (OR 1.9, 1.34 to 2.69, p=0.012). There 
was no difference is decision making preference for patients with CHF, depression, or 
prior MI, PCI, or CABG. Preference for MDM was not associated with patients’ ultimate MI 
treatment (medical treatment vs. PCI vs. CABG).
Conclusions: A high proportion of MI patients want an active role in medical decisions at 
the time of acute MI. Speciﬁc patient characteristics are associated with the active MDM 
role. Additional study is warranted to determine how best to increase patient involvement 
in MDM, as it is unclear if patient preference is driving current treatment decisions.
1086-191 Do Users Of Complementary and Alternative Medicines 
Adhere to Evidence-based Secondary Prevention 
Medications for Coronary Disease as much as Non-
users? Insights From The Inform Registry
Sudeshna Banerjee, John Spertus, Carole Decker, Angela Jones, Mid America Heart 
Institute, Kansas City, MO
Background: Complementary and alternative medicine (CAM) use in the United States 
has risen signiﬁcantly in the last decade. CAM therapies vary from alternative medical 
systems, such as acupuncture, to mind-body therapies including meditation and yoga. A 
potential risk of using CAM is that patients may preferentially use these unproven treatments 
at the expense of evidence-based therapies known to improve outcomes. We examined 
a prospective acute coronary syndrome (ACS) registry to determine whether CAM users 
admitted with a previous cardiovascular condition warranting evidence-based therapies 
were less likely to report using such therapies as compared with non-CAM users.
Methods: A prospective registry of 1,199 ACS patients were enrolled and interviewed 
over a 19-month period at two Midwestern hospitals. CAM use was deﬁned as 
biofeedback, acupuncture, relaxation, home remedies, and/or chelation therapy. CAM use 
was prospectively assessed along with detailed histories of patients’ socio-demographic, 
economic, clinical, and health status. Patients with known coronary artery disease 
 
 (CAD) and without contradictions to speciﬁc medications recommended by established 
guidelines were evaluated for their medication use on admission.
Results: Nearly 50% (596/1199) of patients had previously documented CAD and were 
eligible for secondary prevention medications. Of these, 19% (114/596) reported CAM 
use. CAM users were more likely to be taking a beta-blocker in the setting of CAD (62.6% 
vs. 46.2%, p=0.004) than non-CAM users. No differences in the use of aspirin (73.4% vs. 
74.2%, p=0.86) or statin therapy (61.4% vs. 54.0%, p=0.15) were observed.
Conclusion: In contrast to our hypothesis that CAM users would be less likely to use 
evidence-based secondary prevention measures, we found that CAM users were more 
likely to be taking a beta-blocker in the setting of CAD than their non-CAM using cohorts 
and had similar use of aspirin and lipid-lowering therapies. Deﬁning whether patients 
continued the use of CAM therapies after their ACS and the association of CAM therapies 
with subsequent clinical outcomes is needed in future investigations.
1086-192 Do Patients Who Report Avoiding Care Due to Cost 
Delay Treatment of Their Myocardial Infarction?
Darcy Green Conaway, Erik Schelbert, Jeptha Curtis, Carole Decker, Phil Jones, Harlan 
Krumholz, Eric Peterson, David Cohen, John Spertus, St. Luke’s Hospital, Kansas City, 
MO, University of Missouri-Kansas City, Kansas City, MO
Background: Early presentation in the setting of a myocardial infarction (MI) is associated 
with improved outcomes. Given the growing epidemic of uninsured Americans, we 
hypothesized that patients who reported avoiding healthcare because of cost would have 
a delayed MI presentation time.
Methods: We evaluated 1,245 patients prospectively enrolled from 19 centers participating 
in the PREMIER acute MI registry. Patients were surveyed during MI hospitalization and 
divided into 2 groups: those who stated they avoided healthcare due to cost and those 
who did not. In the primary analysis, we compared the groups for differences in time to 
presentation from symptom onset to presentation. Multivariable linear regression analysis 
was performed to adjust for patient demographics and co-morbidities that were deemed a 
priori as likely to be associated with delay in clinical presentation.
Results: Overall, 29% of the patients (n=236) reported that they avoided healthcare 
because of cost. These patients were more likely to be young (55.4 years of age vs 61.1 
years; p<0.001) and black (20.8% vs13.1% p=0.007), but did not differ in gender (males 
66.1% vs 69.7%; p=0.278) or in terms of the reason for their admission (deﬁnite/probable 
MI 77.% vs 79%, possible MI 14% vs 13.%, unstable angina 9% vs 8%; p=0.788). In 
multivariable analysis, there was no difference from symptom onset to presentation in 
patients who reported avoiding healthcare due to cost.(>0-1hour, 8% vs 8%; >1-6 hr 40% 
vs 45%; >6 hr 51% vs 47%).
Conclusion: Nearly 1 in 5 patients presenting with an MI report avoiding care due to cost. 
Importantly, however, these patients do not delay their care in the setting of an acute MI. 
Whether avoiding care due to costs is associated with less emergent aspects of medical 
care, such as medication compliance or follow-up after discharge is not yet known and 
warrants further study.
1086-193 Quality of Life and Depressive Symptoms:  
Is there a Relation?
Emir Veledar, Jerome Abramson, Christi Deaton, Viola Vaccarino, Pamela Hartigan, 
Cheryl Lewis, Teo Koon, William Boden, Robert O’Rourke, John Spertus, William 
Weintraub, Emory University, Atlanta, GA
Background: Depressive symptoms are known to be associated with cardiac patients’ 
health status (their symptoms, function and quality of life), but have rarely been compared 
with traditional markers of disease severity. We sought to determine the relative importance 
of depressive symptoms vs. traditional measures of disease severity on cardiac patients’ 
health status.
Methods: We conducted a cross-sectional analysis of baseline data from 1707 cardiac 
patients who participated in the COURAGE Trial. Depression was assessed using the 
Mood Screen Form and dichotomized.The Seattle Angina Questionnaire (SAQ) was 
used to assess perceived health status. Traditional risk factors were assessed. Linear 
regression was used to analyze depression as a predictor of SAQ subscales after 
adjustment for physical and other risk factors.
Results: Depression was associated with physical limitation, quality of life, age, living 
alone, female gender, and number of diseased vessels, and was one of the most 
signiﬁcant predictors of health status, independent of the severity of patients’ underlying 
coronary artery disease and other traditional risk factors. In fact, it was among the 
strongest predictors of the SAQ subscales.(P < .05) 
Regression coefﬁcients for signiﬁcant predictors  
of health status by SAQ subscales 
Variable Physical Limitation
Angina 
Stability
Angina 
Frequency
Treat. 
satisfaction
Quality of 
Life
CCS -5.68 -7.58 -10.39 -1.42 -7.66
Depression -9.98 -4.40 -4.80 -2.68 -10.05
Phisical Activity 1.65 0.95
Prior stroke -13.24 -5.56
Prior CAB -7.43 -8.75 -6.84 -6.16
BMI -0.44
Age -0.19 0.14 0.15 0.38
White race 4.96 4.35
Ejection Fraction 
(per 10% dic.) -0.14 -0.12 -0.11
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Conclusion: Depression is strongly associated with heath status among cardiac 
patients, independent of the degree of cardiac disease and other risk factors. Clinicians 
should strongly consider depression levels when managing the health status of cardiac 
patients.
1086-194 Do Depressed Acute Coronary Syndrome Patients 
Receive Cardiac Catheterization Less Often?
Alpesh A. Amin, Angela MH Jones, Karen Nugent, John S. Rumsfeld, John A. Spertus, 
Saint Lukes Hospital, Kansas City, MO, Mid America Heart Institute, Kansas City, MO
Background: Depression is common in acute coronary syndrome (ACS) patients and is 
independently associated with adverse patient outcomes. One possible explanation for 
this is that depressed patients receive less aggressive care at the time of ACS compared 
to non-depressed patients. To evaluate this hypothesis, we investigated the association 
between the severity of depressive symptoms and the likelihood of cardiac catheterization 
in patients presenting with unstable angina (UA) or non-ST elevation myocardial infarction 
(NSTEMI).
Methods: Detailed clinical data were prospectively gathered on 855 patients presenting 
with UA or NSTEMI to two hospitals between March 2001 and November 2002. Depressive 
symptoms were quantiﬁed using the Patient Health Questionnaire-9 (PHQ), which yields 
a score ranging from 0 to 27 with higher values indicating increasing depression severity. 
PHQ scores ≥10 have a sensitivity and speciﬁcity of 88% diagnosing for Major Depression. 
Multivariable logistic regression analysis was used to evaluate the association between 
PHQ scores and receipt of cardiac catheterization during ACS hospitalization, adjusting 
for clinically and statistically signiﬁcant baseline demographic and clinical characteristics.
Results: Out of 855 patients, there were 514 with UA and 341 with NSTEMI. Overall, 655 
(76.6%) patients underwent cardiac catheterization. In univariate analysis, those who did 
not undergo cardiac catheterization had a signiﬁcantly higher PHQ score, indicating more 
depressive symptoms, than those who did undergo catheterization (8.2 vs. 4.9, p<0.001). 
In multivariable analysis, higher PHQ scores were associated with a signiﬁcantly lower 
likelihood of receiving cardiac catheterization during ACS hospitalization (OR 0.81 per 5 
point increase in PHQ, 95 % CI 0.677-0.967, p=0.019).
Conclusion: Cardiac catheterization is performed signiﬁcantly less often in depressed 
patients with UA or NSTEMI than in non-depressed patients. This ﬁnding may, in part, help 
explain why depressed patients are at increased risk for adverse outcomes following ACS.
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1087-185 Face and Content Validation Efforts of the Vascular 
Interventional System Trainer (VIST) for Carotid 
Stenting; Results From the First 100 Physicians to 
Complete the Emory Neuro-Anatomy Carotid Training 
(ENACT) Program
Anthony G. Gallagher, William J. Nicholson, Khusrow Niazi, Tarek Helmy, Puvi Seshiah, 
Anna Kalynych, Christopher U. Cates, Emory University, Atlanta, GA
Background: Interventional Cardiology (IC) procedures confer similar beneﬁts to 
minimally invasive surgery (MIS), such as minimum invasion of the body cavity, reduced 
pain, less recovery time, etc., but also share similar problems. Virtual reality (VR) training 
has been proposed as a potential training solution for IC procedures such as carotid 
angiography and carotid stenting. This paper reports on preliminary efforts at validating a 
full procedural VR simulator for IC: Vascular Interventional System Trainer (VIST).
Methods: Experienced (mean = 3,000 (range 200 - 5,000) endovascular procedures) 
attending physicians (71 interventional cardiologists, 21 vascular surgeons, 7 
cardiothoracic surgeons and 1 interventional radiologist) participating in ENACT completed 
an assessment of the VIST VR simulator after completing a simulation of angiography of 
both carotid arteries. There was 100% completion rate of the assessment.
Results: Assessment was broken down into how the simulation looked, felt and behaved 
during the completion of the carotid procedure and was rated on a 5-point Likert scale 
where 1 = not realistic and 5 = very realistic. Overall, physicians reported that the VIST 
system was a good representation of the neck vasculature with appropriate pathology 
(mean 4.5). However, they also reported that some of the cranial bony structures and 
the intracranial vasculature correlated poorly with actual anatomic structures (mean = 1). 
Subjects were very impressed with the catheter and wire dynamics which they reported 
gave one-to-one haptic correspondence of psychomotor movements of catheters such as 
during push-pull maneuvers (mean = 4.4). Overall the catheter dynamics were rated as 
good. In terms of procedural realism the order that wires and catheters that would be used 
during carotid angiography were the exact same on the simulation (mean = 5).
Conclusions: VIST represents one of the most sophisticated VR simulators in medicine. 
Physicians surveyed in this study reported that it looked, felt and behaved similar to 
working on an actual patient. However, considerably more work is required to validate 
whether this simulator will improve catheter performance on actual patients.
1087-186 Training on a Virtual Catheter Simulator Improves the 
Procedural Skills in Novices of Coronary Interventional 
Procedures- An Experimental Study Using a Pulsatile 
Coronary Flow Duplicator
Wolfram Voelker, Jan Coburger, Martin Laser, Beate Holbach, Jürgen Hesser, University 
of Wuerzburg, Wuerzburg, Germany, University of Mannheim, Mannheim, Germany
Rationale: Progress in computer technology has promoted computer-based simulators. 
CATHI is a virtual simulator, which provides a realistic teaching environment for coronary 
interventions. It has a haptic interface to the original instruments and devices used in the 
cathlab. CATHI produces a synthetic x-ray image of the coronary tree. We assessed the 
hypothesis that CATHI can improve the hand-eye coordination and total procedural quality 
of beginners in coronary interventional procedures.
Methods: Therefore, 12 participants without any experience in interventional cardiology 
were randomized and underwent either simulator training (group 1: n=6) or pure computer 
based training with keyboard and mouse only (group 2: n=6). Afterwards, each test-person 
had to perform a coronary intervention in a pulsatile ﬂow model containing different target 
lesions. The procedure was performed in the cath lab under ﬂuoroscopic guidance. All 
steps of the intervention were objectively assessed according to a standardized form by 
an experienced interventionalist. Thus, an individual “skill-score” was determined, which 
took different aspects of the procedure quality into account, f.e. the usage of the X-ray-
unit, the manipulation of the wire and the catheter, the risk-adapted behaviour and the 
amount of assistance, which was necessary during the procedure.
Results: Simulator training (group 1) resulted in a reduction of procedure time and 
radiation time compared with computer based training (group 2); however, these 
differences were not signiﬁcantly signiﬁcant. In contrast, the “skill-score” was signiﬁcantly 
higher in group 1 than in group 2 (p=0.016).
Conclusion: Training with the virtual simulator CATHI signiﬁcantly improved the 
procedural skills of beginners without any experience in coronary interventions. This may 
partially be explained by the training effect itself, but also by the improved self-conﬁdence 
of the beginner, which can be achieved by simulator training under realistic conditions. 
The teaching effect of CATHI in more experienced interventionalists has to be evaluated 
in further studies.
1087-187 Using Simulated Heart Sounds to Master Cardiac 
Auscultation: A Psychoacoustic Approach
Michael Barrett, Carolyn Lacey, Sweta Chandela, Mark Mascarenhas, George 
Yesenosky, Aditya Mehra, Edward Gracely, Drexel University College of Medicine, 
Philadelphia, PA
Background: The ability of internal medical residents (PGYI-PGYIII) to recognize 
abnormal heart sounds is alarmingly low (~22%) and does not improve during subsequent 
years of training. We tested the hypothesis that cardiac auscultation is a psychoacoustic 
skill that responds to intensive repetition with a prompt increase in proﬁciency. Using 
simulated heart sounds, we studied the effect of 200 repetitions of each of 6 abnormal 
heart sounds on the proﬁciency of medical residents’ skill in cardiac auscultation.
Methods: 33 medical residents were included in this study. Auditory templates of 
abnormal heart sounds were created using digitally enhanced simulated heart sounds on 
a compact disc. In a monitored session all subjects listened to 200 repetitions of each of 
4 cardiac murmurs of (Aortic Stenosis, Mitral Regurgitation, Aortic Regurgitation, Mitral 
Stenosis) and 2 extra heart sounds (S3, S4). Two tests of auscultatory proﬁciency using 
human heart sounds were administered: a pretest before the intervention and a posttest 
several days after the intervention. At both tests, subjects listened to 10 prerecorded 
human heart sounds in a randomized sequence.
Results: The baseline proﬁciency score was 35 +/- 18% (Mean +SD) and increased 
signiﬁcantly to 67 +/- 15% on the posttest, p<0.001 by paired t test. The average improvement 
was 32 points after listening to 200 repetitions of each abnormal heart sound.
Conclusions: Two hundred repetitions of simulated heart sounds signiﬁcantly improved 
medical residents’ ability to recognize human heart sounds. The use of simulated heart 
sounds can produce signiﬁcant improvement in this neglected clinical skill. These results 
are consistent with the hypothesis that cardiac auscultation is a psychoacoustic skill that 
responds to repetition with a signiﬁcant increase in auditory proﬁciency.
1087-188 A Finite Element Model of Electrical Activation 
Sequence in the Ventricles
Frederick J. Vetter, Salvatore A. Chiaramida, University of Rhode Island, Kingston, RI, 
Medical University of South Carolina, Charleston, SC
Background: The electrical activation sequence of the ventricles is an important 
determinant of cardiac pumping efﬁciency. Studies of the temporal distribution of electrical 
excitation in the isolated heart are valuable for understanding the QRS complex and 
arrhythmias in the normal heart. Modeling this data has great utility in formulating cardiac 
pacing and resynchronization therapies since the excitatory effects of such therapies can 
be compared to normal activation. 
Methods: The electrical activation sequence in the ventricles was computed using a two-
dimensional (2D) ﬁnite element model with a realistic geometry. The stimulus originated 
on the LV and RV endocardium, similar to the early activation sequence observed in the 
human heart [Durrer et al. Circulation 41(6):899]. The 2D cable equation was integrated to 
obtain the activation time in the ventricles. 
Results: The model provides the same important characteristics observed in experiments. 
LV epicardial breakthrough of the excitation wave occurred between 30-35 ms in model, 
compared to 35-40 ms in the human data. The base of the septal RV endocardium was 
activated by the wave front originating on the LV endocardium. Wave fronts originating 
near the RV apex activated the basal RV free wall. 
Conclusions: Simulations based on a realistic geometry replicate the dispersion of 
activation in the ventricles. This tool is useful for studying ventricular excitation in the 
healthy and paced heart, and quantifying the efﬁcacy of new pacing strategies.
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1087-190 An Integrated Finite Element and Hemodynamic 
Model for Assessing Hemodynamic Consequences of 
Regional Myocardial Impairments
Rumei Dong, Ying Sun, Frederick J. Vetter, Salvatore A. Chiaramida, University of Rhode 
Island, Kingston, RI, Medical University of South Carolina, Charleston, SC
Background: A ﬁnite element model of the left ventricle (LV) was fully integrated into a 
complex hemodynamic model to study relations between regional myocardial impairment 
and hemodynamics. Method: A 3D LV model was reconstructed from two 2D grids, one 
for normal myocardium and the other containing an infarct zone. Contractility was deﬁned 
by assigning different time-varying functions of Young’s modulus to normal and infarct 
elements. The ﬁnite element model was computed at a time step of 5 ms and interacted 
dynamically with an electrical analog model governed by 28 differential equations. Given 
an infarct size the model generated hemodynamic curves continuously for many cardiac 
cycles to reveal transient and steady state responses. Simulations of normal and impaired 
LVs with various infarct sizes were performed. Result: Figures below show end-systolic 
and end-diastolic LV chambers for an infarct size of 18% LV mass. Pressure and volume 
curves predicted by the model showed reduction in LV functions and elevation of LV 
preload, which were consistent with data in the literature. Conclusion: The integrated 
model provides a new platform for relating regional myocardial impairment to its effects 
on global hemodynamics. The model should be a useful research and educational tool for 
assessing severity of infarction and planning for LV remodeling surgeries.
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1115-181 Adverse Drug Events in Cardiology and Cardiac 
Surgical Patients
John Fanikos, Jennifer Cina, Camilla Huber, Steven Baroletti, Samuel Z. Goldhaber, 
Rene Quiroz, Brigham and Women’s Hospital, Boston, MA
Background: Adverse drug events (ADEs), comprised of medication errors and adverse 
drug reactions, are a major problem in the care of patients. We reviewed reported ADEs in 
cardiology and cardiac surgical patients to determine the rate, the medications, severity, 
preventability, and the stage of the medication use process involved.
Methods: We searched our reporting system for all ADEs occurring in Cardiology 
and Cardiac Surgical patients from 1999 through 2004. All ADEs were reviewed by a 
multidisciplinary panel, analyzed for preventability, and scored for severity.
Results: We identiﬁed 659 ADEs: 426 adverse drug reactions and 233 medication 
errors. 56% of ADEs were deemed preventable. Overall there were 2.1 ADEs for every 
100 Cardiology admissions and 5.4 ADEs per 1000 patient days compared to 4.2 ADEs 
for every 100 Cardiac Surgery admissions and 2.7 ADEs per 1000 patient days. There 
were no ADE related deaths but injury or prolonged hospital stay occurred in 7.8% of 
patients. Cardiovascular medications were involved in 218 (31.8%) of all reported ADEs, 
followed by anticoagulants 177 (26.8%). Of the medication errors, 132 (56.7%) occurred 
at administration, 53 (22.7%) during transcription, 26 (11.2%) at pharmacy dispensing, 
and 17 (7.3%) during physician prescribing.
Conclusions: ADEs complicate care of hospitalized Cardiology and Cardiac Surgical 
patients. Our data indicate that ADEs occur frequently with the medications that are 
commonly used in this population, and in most cases can be prevented.
Adverse Drug Events Totals n (%) Cardiac Surgery n (%)
Cardiology
n (%) p value
Adverse Drug Reactions 426 (64.6) 136 (20.6) 290 (44.0) <0.001
Medication Errors 233 (35.4) 77 (11.7) 156 (23.7) <0.001
Total ADES 659 (100) 213 (32.3) 446 (67.7) <0.001
Preventable ADEs 370 (56.2) 123 (18.7) 247 (37.5) < 0.001
Event Rate per 100 Admissions 2.5 4.2 2.1 <0.001
Event Rate per 1000 Patient Days 4.1 2.7 5.4 <0.001
Injury or Prolonged Hospitalization 51 (7.8) 17 (2.6) 34 (5.2) 0.02
Cardiovascular agents 218 (31.8) 48 (7.3) 170 (25.8) <0.001
Anticoagulants 76 (11.5) 76 (11.5) 101 (15.3) 0.07
Antimicrobials 23 (3.5) 23 (3.5) 43 (6.5) 0.02
Other 71 (10.0) 71 (10.0) 132 (20.1) <0.001
1115-182 Cath Lab Based Renal Protection Protocols Reduce Dye 
Induced Hemodialysis
Aaron Kugelmass, Allan Anderson, Lynn Tarkington, Salvatore Battaglia, Steven Culler, 
Edmund Becker, April W. Simon, Emory University, Atlanta, GA, HCA, Inc., Nashville, TN
Background: Utilizing a renal protection protocol (RP) that includes, identifying a 
patient’s creatinine level, calculating maximum contrast dose, and periodically notifying 
the cardiologist of contrast load during the cath lab encounter, has been suggested to 
reduce dye induced renal failure. We examine the impact of renal protocols on a large 
sample of cath lab patients in a group of 25 community-based hospitals.
Methods: Using the HCA Casemix Database, a comprehensive database of all 
consecutive patients in HCA hospitals, a sample of 25 hospitals were surveyed over the 
10-quarter period January 2002 through June 2004 related to use of a RP for cath lab 
patients. All cath lab patients (excluding those that received a CABG) in these hospitals 
were analyzed in a pre-post research design. Cath patients, co-morbid conditions, 
procedures, and complications were identiﬁed through ICD-9 coding. Univariate and 
logistic regression analyses controlling for 25 patient characteristics, comorbid conditions, 
and procedural variables were used to analyze in-hospital mortality, acute renal failure 
(ARF), and patients requiring hemodialysis (HEMO) for the ﬁrst time.
Results: Of the 58,863 cath lab patients in our study sample, 11,814 (20.1%) underwent 
cardiac cath with a RP. Univariate results show that compared with patients who underwent 
cathe without a RP in place, RP patients experienced signiﬁcantly less HEMO (0.95% 
vs. 1.45%; p<0.001), as well as lower mortality rates (1.24% vs. 1.39%; p=.224) and 
slightly lower ARF rates (2.54% vs. 2.56%; p=.909). After controlling for patient comorbid 
conditions, procedural characteristics, and hospital characteristics, the logistic regression 
results demonstrated that patients who underwent cath with RP were 60.1% less likely to 
require HEMO (p<0.001). RP did not signiﬁcantly reduce Mortality or ARF.
Conclusions: This study demonstrates that the institution of RP in community based 
cardiac cath practice markedly reduces the incidence of dye induced nephropathy 
requiring HEMO. Efforts should be made to broadly implement RP protocols in cath lab 
practices.
1115-185 Examining the Variation in Complication Rates Among 
Medicare Beneﬁciaries Undergoing Coronary Artery 
Bypass Graft Surgery Across Hospital Performance 
Deciles
Phillip Brown, Aaron Kugelmass, Edmund Becker, Steven Culler, April W. Simon, Emory 
University, Atlanta, GA, Centennial Medical Center, Nashville, TN
Background: While variation in mortality rates is well known among hospitals performing 
CABG surgery, it is not known if complication rates (post-operative stroke and acute renal 
failure (ARF)) vary in a consistent manner across hospital performance deciles based 
on lives saved.
Methods: A retrospective analysis was conducted using the Medicare Provider Analysis 
and Review Files. The study sample consists of 144,681 Medicare beneﬁciaries who had 
CABG surgery in one of 1,059 hospitals during ﬁscal year 2002. The Yale R-DRG Grouper 
program was used to assign patients into three levels of severity: low, medium, and high. 
National and individual hospital survival and complication rates were calculated for each 
severity level. Hospitals were ranked into deciles based on the total number of lives saved, 
with performance tier 1 being the hospitals saving the most lives. Quartile values were 
calculated for the hospital’s average complication rates by performance decile.
Results: The median complication rate was 2.1%, while approximately one-fourth of the 
hospitals had average complication rates below 0.75% or above 3.4%. A similar range in 
the quartile values for complication rates remained across all performance deciles and 
the median complication rate did not decline consistenly as one moves from the worst 
to the best performance tiers. The Spearman correlation coefﬁcient between the rank 
order of lives saved and rank order of complication rate indicated that the two ranks are 
independent.
Conclusions: The fact that approximately one-fourth of the hospitals in each of the 10 
perfromance tiers have risk-adjusted complication rates that are 50% higher than national 
average complication rates suggest that hospital performance rankings should not be 
based only on a single outcome measure.
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1115-186 How Do Acute Percutaneous Coronary Intervention 
Complication Rates Vary In Hospitals Ranked in the Top 
versus the Bottom Quartile of Hospitals?
Aaron Kugelmass, Phillip Brown, Edmund Becker, Steven Culler, April W. Simon, Emory 
University, Atlanta, GA, Henry Ford Health System, Detroit, MI
Background: This abstract examines the differences in PCI complication rates for 
hospitals ranked in the top quartile versus the bottom quartile for mortality.
Method: This retrospective analysis was conducted using the Medicare Provider Analysis 
and Review (MedPAR) ﬁles for ﬁscal year 2002. The study sample consists 335,477 PCI 
admissions. National and individual hospital average survival rates are calculated by 
severity level. The sum of lives saved is used to rank hospital performance into quartiles. 
Complication rates, for three acute PCI complications (emergency CABG, new onset 
hemodialysis, and post operative stroke) is calculated for 265 hospitals ranked in the top 
and bottom quartile of all hospitals.
Results: By deﬁnition of the ranking process, the average hospital mortality rate for 
hospitals in the top quartile (1.04%) is less than in the bottom quartile (3.45%), this 
difference results in 70.6% reduction in the relative risk between top and bottom tiered 
hospitals. Hospitals in the top quartile have lower post-operative stroke rates (0.18% vs. 
0.23%) and emergency CABG rates (1.09% vs. 1.35%). There was no difference in the 
rate of new onset hemodialysis between top and bottom hospitals.
Conclusions: In addition to reducing their relative risk of mortality, patients can 
signiﬁcantly reduce the relative risk of post-operative stroke and emergency CABG 
surgery by choosing to have their PCI procedure done in hospitals ranked in the top 
quartile versus the bottom quartile.
Top Quartile Bottom Quartile Relative Risk Reduction
Mortality 1.04% 3.45% 70.6%
Post-Procedural Stroke 0.18% 0.23% 21.7%
New Onset Hemodialysis 0.92% 0.92% 0.00%
Emergency CABG 1.09% 1.35% 19.3%
1115-187 Racial Differences in Health Status in Patients 
Hospitalized with Acute Coronary Syndromes: Findings 
from the Prospective Registry Evaluating Outcomes 
After Myocardial Infarction Events and Quality 
Improvement Registry (PREMIER-QI)
Saif S. Rathore, Jeptha P. Curtis, Philip M. Jones, Erik M. Schelbert, Frederick A. 
Masoudi, John S. Rumsfeld, Susmita Mallik, Viola Vaccarino, Eric D. Peterson, John A. 
Spertus, Harlan M. Krumholz, for the PREMIER-QI Investigators, Yale University School 
of Medicine, New Haven, CT, Mid America Heart Institute, Kansas City, MO
Background: Although health status at presentation is known to predict mortality in 
patients hospitalized with MI have higher mortality than white patients, limited data is 
available regarding racial differences in health status.
Methods: We utilized data from PREMIER-QI, a prospective registry enrolling patients 
hospitalized MI at 19 centers in the US between 1/2003-6/2004. Analysis was limited to 
patients whose self-reported race was black or white and had a conﬁrmed MI (n=2,372). 
Patient health status was assessed using the Seattle Angina Questionnaire (SAQ), 
which was administered during the patient’s hospitalization. We compared three SAQ 
subscales- functional status, symptom burden, and quality of life (all scored from 0 to 
100, higher scores indicating better health status). Unadjusted and multivariable linear 
regression analyses were conducted to assess whether racial differences in subscale 
scores were attributable to differences in site of treatment and patient characteristics.
Results: Black patients were 22% (n=531) of the cohort. Black patients reported worse 
crude mean functional status (69.5 vs. 87.4, p<0.001), quality of life (54.0 vs. 64.5, 
P<0.001), and symptom burden (81.2 vs. 84.2, P=0.006) compared with white patients. 
Racial differences were reduced after adjustment for site of treatment for functional status 
(78.1 black vs. 82.7 white, P=0.003) and quality of life (58.8 black vs. 61.8 white, P=0.03), 
and attenuated for angina frequency (83.3 black vs. 81.4 white, P=0.15). Patients’ 
adjusted mean functional status (78.8 black vs. 80.9 white, P=0.16), symptom burden 
(84.4 black vs. 82.3 white, P=0.12), and quality of life (60.3 black vs. 61.7 white, P=0.32) 
were comparable after adjustment for patient characteristics.
Conclusion: Although black patients hospitalized with MI report worse health status 
than white patients, these differences appear to be attributable to differences in site of 
treatment rather than patient race itself. These data highlight the importance of accounting 
for differences in site of treatment and other patient characteristics when comparing racial 
differences in health status among patients with cardiovascular disease.
1115-188 Drug Cost-sharing Policies: Adverse Effects in Medicare 
Patients Taking Statins
John Hsu, Jie Huang, Richard Brand, Bruce Fireman, Rita Hui, Joseph P. Newhouse, 
Joseph V. Selby, Kaiser Foundation Research Institute, Oakland, CA, Harvard University, 
Boston, MA
Background: Ongoing changes in prescription drug coverage could have signiﬁcant 
clinical consequences. We investigated the impact of a $1,000 annual drug beneﬁt cap 
versus no cap on drug consumption, adherence, and physiologic outcomes in 2003 
among Medicare patients who were using statin drugs in the previous year.
Methods:  We examined the cap effect in patients 65 years and older with Medicare 
insurance, who were receiving statins in 2002, and who had a $10 copayment for generic 
drugs plus a $20-35 copayment for brand name drugs. All subjects were members of 
Kaiser Permanente-Northern California, an integrated, prepaid delivery system. Subjects’ 
former employers determined whether subjects had the cap or not. We used linear and 
logistic regression models to examine the association between having a cap and drug 
consumption in 2003 (in dollars), between the cap and drug adherence, as measured 
by the proportion of days covered (PDC), and between the cap and having elevated lipid 
levels (last value in the year). We adjusted for age, gender, race/ethnicity, socioeconomic 
status, comorbidity (DxCG scores) and medical centers.
Results:  Among the 54,797 subjects in 2003, 78.6% of subjects had a $1,000 annual 
drug beneﬁt cap, and the remaining subjects had no beneﬁt limit; 89.5% and 87.8% of 
non-cap and cap subjects had ≥1 lipid test in 2003. Drug consumption ($) among subjects 
with a cap was 25.9% lower for all drugs and 21.3% lower for statin drugs, compared to 
subjects without a cap (both p-values<0.0001). Adherence (PDC≥0.8) was lower for statin 
drugs (OR=0.80, 95% CI: 0.76-0.83) in subjects with a cap compared to no cap. Lipid 
levels also were worse among subjects with a cap compared to no cap: OR=1.09 (95% 
CI: 1.03-1.16) for LDL>130.
Conclusion:  While the rising costs of prescription drugs pose signiﬁcant health care 
challenges in the United States, these preliminary data suggest that approaches involving 
limitations of seniors’ drug coverage may have adverse clinical effects in patients requiring 
chronic prescription drugs. Additional analyses will investigate the impact of beneift caps 
on other unfavorable clinical events.
1115-189 The Relationship Between Quality of Care and 
Reimbursement for Patients Hospitalized with Heart 
Failure
Edward P. Havranek, Pam Wolfe, Frederick A. Masoudi, JoAnne M. Foody, Saif S. 
Rathore, Harlan M. Krumholz, Denver Health Medical Center, Denver, CO, Yale 
University School of Medicine, New Haven, CT
Background: Reimbursing higher quality care at a higher rate has been proposed as 
a means of improving healthcare quality. Government and private payers have initiated 
programs to assess this approach, but there are limited data on the relationship between 
reimbursement and quality of care.
Methods: We obtained two measures of quality of care for 34,318 patients across the 
United States hospitalized with heart failure: documentation of ejection fraction (EF) 
and the prescription of an ACE inhibitor when systolic dysfunction is present. Data were 
obtained by chart review as part of the National Heart Failure project, a Medicare quality 
improvement effort. For each of the 3,905 hospitals at which one of these patients was 
admitted, the hospital’s reimbursement for the heart failure Diagnosis-Related Group 
(DRG) was calculated from publicly available ﬁles. We assessed for an association 
between the quality measures and DRG payment with hierarchical logistic regression 
models, controlling for the hospital’s teaching status, urban/rural location, and proportion 
of reimbursement from Medicare. We also compared hospital characteristics by 
dichotomized DRG level using chi-square tests for equal proportions.
Results: We found a discontinuous relationship between documentation of EF 
measurement and DRG payment. Above a threshold of $4200, hospitals’ rates of EF 
measurement did not increase with increasing reimbursement. Below that threshold, 
there was a steep increase in rates of the quality indicator with increasing DRG payment 
(OR 1.15 for each $100 increase, 95% CI 1.12-1.18). For ACE inhibitor prescription, the 
increase in rates below the threshold was of borderline signiﬁcance (OR 1.04 for each 
$100 increase, 95% CI 1.00-1.07). Hospitals with reimbursement below the threshold 
were more likely non-urban (p<0.001), public (p<0.0001), and without advanced cardiac 
facilities (p<0.0001), and had fewer full-time nurses per adjusted patient-day (p<0.0001).
Conclusions: Hospitals with low rates of Medicare DRG-based reimbursement have 
lesser performance on heart failure quality indicators, perhaps because of difﬁculty 
investing in technology or maintaining stafﬁng.
1115-190 Does Patient Age Impact the Use of Evidence-Based 
Heart Failure Therapies at Hospital Discharge? A Report 
From the Organized Program to Initiate Lifesaving 
Treatment in Hospitalized Patients With Heart Failure 
(OPTIMIZE-HF)
Gregg Fonarow, William T. Abraham, Nancy M. Albert, Wendy Gattis, Mihai 
Gheorghiade, Barry Greenberg, Chris M. O’Connor, Lilin She, Clyde W. Yancy, James B. 
Young, UCLA Medical Center, Los Angeles, CA
Background: OPTIMIZE-HF is designed to improve medical care and education 
of hospitalized HF patients, and to accelerate the use of evidence-based, guideline 
recommended therapies by initiating them prior to hospital discharge. This analysis 
assesses the role of patient age in the use of guideline recommended therapies in eligible 
patients at the time of hospital discharge.
Methods: OPTIMIZE-HF has 2 major components, a web-based registry and a process-
of care intervention arm. Consecutive hospitalized HF patients were enrolled. The data 
are reported as the number and frequency of eligible patients treated at time of hospital 
discharge, excluding patients with documented contraindications or intolerance.
Results: This analysis included 33,883 patients from 236 US hospitals. Of these, 11,780 
patients were ≤ 70 and 22,103 were > 70 years of age. Older patients were more likely 
to be female, caucasian, have atrial ﬁbrillation, CAD etiology, and preserved systolic 
function. Older patients were signiﬁcantly less likely to have LV function measured, 
receive complete discharge instructions, and be treated with evidence-based therapies 
compared to younger HF patients.
Conclusions: Signiﬁcant age-related differences in the provision of guideline 
recommended care to eligible heart failure patients persist even after implementation of 
a hospital improvement system. Further studies are needed to identify factors accounting 
for and additional strategies to overcome these age-related gaps in HF care.
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Characteristics Age<=70 Age>70 OR (95%CI) P-value
N (%) Male 6689/11779 (56.79%) 9608/22103 (43.47% ) 0.59 (0.56, 0.61) <.0001
N (%) Caucasian 7071/11543 (61.26%) 18290/21482 (85.14% ) 3.62 (3.44, 3.82) <.0001
N (%) Ischemic Etiology 4774/11780 (40.53%) 10651/22103 (48.19% ) 1.36 (1.30, 1.43) <.0001
N (%) HF with Preserved 
Systolic Function (EF>40) 3020/9055 (33.35%) 7431/15680 (47.39% ) 1.80 (1.71, 1.90) <.0001
N (%) Atrial Fibrillation 2220/11780 (18.85%) 8146/22103 (36.85% ) 2.51 (2.38, 2.65) <.0001
N (%) Diabetes Mellitus 5797/11780 (49.21%) 8331/22103 (37.69% ) 0.62 (0.60, 0.65) <.0001
N (%) Discharge Instructions 
Complete 5729/11420 (50.17%) 9547/20830 (45.83% ) 0.84 (0.80, 0.88) <.0001
N (%) LV Function 
Measurement
10376/11780 
(88.08%) 18512/22103 (83.75% ) 0.70 (0.65, 0.75) <.0001
N (%) ACE Inhibitor Use at 
Discharge, LVD 3538/4485 (78.89%) 3854/5497 (70.11% ) 0.63 (0.57, 0.69) <.0001
N (%) Smoking Cessation at 
Discharge 2195/3547 (60.87%) 950/1685 ( 56.38% ) 0.83 (0.74, 0.93) 0.002
N (%) ACEI and/or ARB Use 
at Discharge, LVD 3991/4673 (85.41%) 4617/5801 (79.59% ) 0.67 (0.60, 0.74) <.0001
N (%) Beta Blocker Use at 
Discharge, LVD 3982/4709 (84.56%) 4652/5917 (78.62% ) 0.67 (0.61, 0.74) <.0001
1115-191 Can Gender Related Disparities in the Use of Evidence-
Based Therapies for Heart Failure Be Reduced? 
A Report from The Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients with Heart 
Failure (OPTIMIZE-HF)
Gregg Fonarow, William T. Abraham, Nancy M. Albert, Wendy A. Gattis, Mihai 
Gheorghiade, Barry Greenberg, Chris M. O’Connor, Lilin She, Clyde W. Yancy, James 
Young, UCLA Medical Center, Los Angeles, CA
Background: Prior studies have shown that women with heart failure (HF) are less 
likely to be treated with guideline recommended therapies then men. Whether hospital 
based systems for HF care can reduce gender related gaps in the use of evidence based 
therapies at the time of hospital discharge has not been well studied.
Methods: OPTIMIZE-HF is a hospital based system with two major components, a 
web-based registry and a process-of care intervention arm. Consecutive hospitalized 
HF patients were enrolled. The data are reported as the number and frequency of 
eligible patients treated at time of hospital discharge, excluding pts with documented 
contraindications or intolerance.
Results: This analysis included 34,057 patients from 236 US hospitals. Of these, 17,680 
were women and 16,377 were men. Female HF pts were older, less likely to have CAD, 
more likely to have preserved systolic function. Post-intervention, eligible women with 
LV dysfunction were equally likely as men to be treated with ACEI and/or ARB and beta 
blockers at time of hospital discharge as well as receive smoking cessation counseling. 
Women remained less likely to receive complete HF discharge instructions.
Conclusions: OPTIMIZE-HF was associated with reduced gender-related disparities in 
the provision of HF care, with comparable use of evidence-based HF medications at time 
of hospital discharge for men and women. This study provides further evidence to support 
the use of hospital systems to improve the quality of HF care. 
Characteristics Women Men OR (95%CI) P-value
N (%) Age>70 yrs 12495/17585 (71.1%) 9608/16297 (59.0%) 0.59 (0.56, 0.61) <.0001
Mean (SD) Age 75.43 (13.5) 70.91 (13.8) <.0001
N (%) Caucasian 13184/17229 (76.5%) 12306/15966 (77.08%) 1.03 (0.98, 1.09) 0.23
N (%) Ischemic Etiology 6778/17680 (38.3%) 8729/16377 (53.3%) 1.84 (1.76, 1.92) <.0001
N (%) HF with Preserved 
Systolic Function (EF>40) 6644/12383 (53.7%) 3861/12473 (31.0%) 0.39 (0.37, 0.41) <.0001
N (%) Atrial Fibrillation 5293/17680 (29.9%) 5121/16377 (31.3%) 1.06 (1.02, 1.11) 0.008
N (%) Diabetes Mellitus 7391/17680 (41.8%) 6818/16377 (41.6%) 0.99 (0.95, 1.04) 0.75
N (%) Discharge Instructions 
Complete 7600/16811 (45.2%) 7762/15610 (49.7%) 1.20 (1.15, 1.25) <.0001
N (%) LV Function 
Measurement 14814/17680 (83.8%) 14219/16377 (86.8%) 1.27 (1.20, 1.35) <.0001
N (%) Smoking Cessation at 
Discharge 1191/2056 (57.9%) 1919/3177 (60.4%) 1.11 (0.99, 1.24) 0.075
N (%) ACE Inhibitor Use at 
Discharge, LVD 2855/3919 (72.9%) 4572/6111 (74.8%) 1.11(1.01, 1.21) 0.028
N (%) ACEI and/or ARB Use at 
Discharge, LVD 3396/4149 (81.9%) 5254/6377 (82.4%) 1.04 (0.94, 1.15) 0.48
N (%) Beta Blocker Use at 
Discharge, LVD 3340/4131 (80.9%) 5337/6547 (81.5%) 1.04 (0.95, 1.15) 0.39
1115-192 Cardiologists Provide Less Cost-Effective Care to 
Medium-Risk Chest Pain Patients
Charles A. Henrikson, Laura C. Plantinga, Eric E. Howell, Neil R. Powe, Nisha Chandra-
Strobos, Johns Hopkins Medical Institutions, Baltimore, MD
Background: Patients admitted with chest pain may be cared for by various providers in 
various locations in most hospitals. Cardiologists, who are used to evaluating patients with 
coronary artery disease, may overevaluate and overtreat such patients in whom a less 
aggressive workup may be appropriate.
Methods: We studied costs, length of stay, and four-month outcomes in 459 patients 
admitted with suspected myocardial ischemia to 5 services in the hospital: cardiac care 
unit (CCU), progressive care unit (PCU), housestaff medicine (HS), nurse practitioner 
(NP), and emergency department extended stay. We compared the 3 services to which 
a patient with moderate risk is generally admitted: PCU (cardiology supervised), HS 
(general medicine supervised), and NP (hospitalist supervised).
Results: A total of 322 patients were admitted to the above three services, with 58 to 
the PCU, 98 to HS, and 166 to NP. There was a gradient of illness severity across these 
services, with mean case mix indices of 0.65 +/-0.29 (PCU), 0.62 +/- 0.34 (HS), and 0.53 
+/-0.20 (NP) (p=0.005 for trend). PCU patients were more likely to have hypertension, 
hypercholesterolemia, and a known history of coronary artery disease, as compared to 
patients admitted to HS and NP services. When stratiﬁed by diagnostic related group 
(DRG) level after adjustment for baseline differences (including demographic and clinical 
factors, case mix index, and cardiac testing results), patients with a lower DRG (who were 
less sick) had the longest length of stay if on the PCU service (p<0.05). Propensity scores 
revealed that patients admitted to the PCU had higher costs than those admitted to the HS 
service. The increase in costs on the PCU stemmed from higher diagnosis and treatment 
costs, while hospital costs were not different on the three services. Clinical outcomes were 
not different between the three services.
Conclusions: In medium-risk patients with chest pain, cardiologist-driven care on the 
progressive care unit results in longer and more expensive care. This is attributable to 
excessive cardiac testing, and does not result in any differences in four-month clinical 
outcomes.
1115-193 Assessing the Economic Attractiveness of Coronary 
Artery Revascularization in Chronic Kidney Disease 
Patients
Eric L. Eisenstein, Jie L. Sun, Kevin J. Anstrom, Daniel B. Mark, Duke Clinical Research 
Institute, Durham, NC
Background: Chronic kidney disease (CKD) is associated with increased morbidity and 
mortality in coronary artery disease (CAD) patients. However, CKD’s impact upon the 
medical costs and survival beneﬁts associated with speciﬁc CAD treatment strategies 
is not known. We compared the economic attractiveness of CAD revascularization 
procedures in patients with and without CKD.
Methods: Our population included 6,218 patients with signiﬁcant CAD undergoing 
cardiac catheterization at Duke University between 1996 and 2001, with follow-up through 
2002. Patients were stratiﬁed by extent of CAD. After adjusting for differences in baseline 
characteristics, we investigated the inﬂuence of CKD (creatinine clearance < 60 mL/min) 
upon 3-year survival and medical costs among patients receiving coronary artery bypass graft 
(CABG) surgery, percutaneous coronary intervention (PCI), and Medical Therapy (MED).
Results: Patients with CKD had more congestive heart failure, vascular disease, and 
severe CAD (i.e., three-vessel or left main disease) than patients without CKD. Patients 
receiving PCI had less extensive CAD while those receiving CABG surgery had more 
extensive CAD. In both CKD groups, CABG surgery was an economically attractive 
alternative (dominant or cost <$55,000 per year of life saved) to MED in all patients with 
left main CAD, and to PCI in all patients with three-vessel CAD. PCI was a marginally 
attractive alternative ($100,000 - $150,000 per year of life saved) to MED for single-
vessel CAD patients in both CKD groups. However, there were CAD treatment strategy 
differences in two-vessel CAD patients: CABG was economically attractive vs. PCI and 
MED among patients with CKD; whereas in patients without CKD, PCI was marginally 
attractive vs. MED and dominant vs. CABG.
Conclusion: CKD is associated with greater cardiovascular disease burden, reduced 
survival, and higher medical costs in CAD patients. While the relative economic 
attractiveness of CAD revascularization procedures is largely similar among patients, with 
and without CKD, there were differences among two-vessel CAD patients. In this subgroup 
CABG was favored for patients with CKD and PCI was favored for those without CKD.
1115-194 Do Cardiologists Follow Their Own Recommendations?
Hussam Abuissa, James O’Keefe, Jr., John Spertus, Mid America Heart Institute, 
Kansas City, MO
Background: In the cardiology community and in the lay press, there is a keen interest 
about what steps cardiologists are personally taking to stay healthy. Cardiologists are 
charged with communicating the latest recommendations for improving health and 
longevity to their patients. How well they comply with these measures themselves is not 
well documented.
Methods: We surveyed all cardiologists in a large coalition of cardiology groups, the 
Cardiology Leadership Alliance (CLA). A one-page, 25-item questionnaire was used. This 
contained three sections: baseline characteristics, medical illnesses and medications. An 
e-mail explaining our project was sent to the administrative assistants in the different 
institutions included in the coalition who were then asked to forward it to their cardiologists. 
Questionnaires, each accompanied with an explanatory letter as well as a pre-addressed, 
stamped envelope, were then mailed to these assistants to distribute to the cardiologists 
in their respective institutions to ensure conﬁdentiality.
Results: 715 surveys were sent and complete data are available for analysis on 
364 thus far. A preliminary analysis was performed on these. The average age of the 
participants is 48 years; 6% are females. Average BMI is 25 kg/m2; 7.8% are obese (BMI 
>30); 13% are former smokers; 2% are current smokers; 88% exercise at least once 
or twice per week and 72% drink at least 1 or 2 drinks per week. Red wine is used 
by 70% of the cardiologists who drink. The rates of medical illnesses are: hypertension 
14%, diabetes 0.8%, dyslipidemia 28%, coronary artery disease 5% and family history of 
premature coronary artery disease 24%. The percentages of cardiologists taking different 
medications are: aspirin 37%, statins 29%, ﬁsh oil 15%, vitamin B6/B12/folic acid 18%, 
vitamin E 10%, niacin 6%, angiotensin-converting enzyme inhibitors 10.2%, angiotensin 
receptor blockers 6% and beta-blockers 7%. 
Conclusion: Cardiologists appear to be following a generally healthy lifestyle, with rates 
of obesity, smoking, sedentary habits and untreated cardiovascular risk factors far below 
those noted in the average adult American population.
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827  Risk Assessment and Care for Patients 
With Cardiovascular Disease
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 230B
4:00 p.m.
827-3 Validity Of TIMI Risk Index And Grace Risk Model In An 
Unselected Myocardial Infarction Population
Pamela J. Bradshaw, Jack Tu, Linda Donovan, Alice Newman, Institute of Clinical 
Evaluative Sciences, Toronto, ON, Canada
Background: Models for stratiﬁcation of risk for in-hospital death after acute MI have been 
developed from clinical trial and registry data but few have been validated in independent 
population-based data sets. We sought to evaluate the predictive power of the TIMI Risk 
Index, a simple index derived from a clinical trial of ST-elevation MI (STEMI) and the 
more complex GRACE risk model based on data from a less-selected multinational acute 
coronary syndrome (ACS) registry.
Methods: The TIMI index and GRACE score were calculated for 11,381 patients in the 
EFFECT study. EFFECT is a population-based registry of AMI patients randomly selected 
from 103 participating hospitals in Ontario, Canada, admitted between April 1999 and 
March 2001. The relationship between both sets of scores and in-hospital deaths was 
examined using the chi-square test and the predictive value of each was assessed with 
measurement of the area under the curve (AUC) of the receiver operating curve (ROC).
Results: Both models were signiﬁcantly associated with in-hospital death (Table 1). The 
AUC (95% Conﬁdence Interval) was 0.85 (0.83-0.86) for the GRACE model, and 0.80 
(0.79-0.82) for the TIMI Risk Index
Conclusions: Both models were highly correlated with in-hospital death, and the very 
simple TIMI Risk Index performed almost as well as the more complex GRACE model, 
conﬁrming its usefulness as a quick and reliable assessment tool for early risk stratiﬁcation 
among unselected patients with both STEMI and non-STEMI.
In-hospitality mortality (%) by GRACE and TIMI risk models 
GRACE
Decile 1 2 3 4 5 6 7 8 9 10
Deaths %
0.1 0.5 0.7 2.3 3.8 5.4 7.2 13.8 19.0 39.7
TIMI
Risk Index <10 10-20 20-30 30-40 40-50 50-60 60-70 70-80 >80
n 652 3 270 2 989 1 981 1 131 596 356 179 227
In-hospital
death % 0.8 1.4 5.0 10.9 19.8 27.5 31.2 40.2 48.9
4:15 p.m.
827-4 The Contribution of Concomitant, Acute Non-Cardiac 
Conditions on In-Hospital Mortality Among AMI Patients
Judith H. Lichtman, Kimberly Reid, Jennifer Mattera, Carole Decker, Fred Masoudi, John 
Spertus, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT, Mid-
America Heart Institute, Kansas City, MO
Background: Risk models for patients with AMI have focused primarily on variables 
directly related to cardiovascular disease and fail to account for much of the variation in 
outcomes among patients. We hypothesize that a substantial proportion of AMI patients 
present to the hospital with acute, potentially life-threatening non-cardiac conditions that 
merit admission in their own right and account for a disproportionate percentage of total 
inpatient deaths.
Methods: We examined in-hospital mortality among AMI patients prospectively enrolled 
from 19 hospitals participating in the PREMIER Registry from 1/1/03-6/29/04. Potentially 
life-threatening (PLT) acute non-cardiac conditions at admission were abstracted from 
patient records and included severe pneumonia, trauma, stroke, severe GI bleed/anemia, 
sepsis, hip fracture, and other conditions. We examined the independent contribution 
of these conditions on mortality by sequentially adjusting for demographic factors, 
medical history, clinical presentation, and initial treatment factors in multivariable logistic 
regression models.
Results: The study included 3948 AMI patients, of whom 8% (n=309) presented with an 
acute PLT non-cardiac condition at admission. In-hospital mortality was 20% (63/309) 
for these patients as compared with 3% (94/3584) for patients without these acute 
concomitant conditions. Patients with these additional PLT events tended to be older, 
female, non-white, had more comorbid conditions, and were less likely to receive initial 
therapies (p<0.001 respectively). In multivariable analysis, the presence of these acute 
PLT non-cardiac conditions remained strongly associated with mortality after adjusting for 
demographic factors (OR 8.5, 95% CI 5.8-12.4), prior history (OR 7.2, 95% CI 4.8-10.7), 
clinical presentation (OR 5.9, 95% CI 3.9-8.9), and initial therapies (95% CI 4.9, 3.2-7.5).
Conclusions: Almost 1 in 12 AMI patients present with concomitant, potentially LT 
acute non-cardiac conditions, which are associated with a ﬁve-fold increase in mortality. 
Despite the prognostic importance of these conditions, they are not included in current 
risk adjustment models for AMI patients.
4:30 p.m.
827-5 How Many Patients Are At “Intermediate Risk” For 
Cardiovascular Disease? Fewer Than You Think - 
NHANES1999-2000
Jon G. Keevil, Mary L. Zasadil, Patrick E. McBride, James H. Stein, University of 
Wisconsin Medical School, Madison, WI
Background: The growing literature of new tests for coronary heart disease (CHD) risk 
assessment focuses on the “intermediate risk group” (IRG), however there are no reliable 
estimates of its size, despite claims of it being 40% of Americans. There are multiple 
deﬁnitions of IRG. ATP III deﬁnes IRG as those without CHD or CHD risk equivalents but 
with multiple risk factors (MRF) and a 10-year Framingham risk estimate (FRE) of 10-
20%. The ACC 34th Bethesda Conference deﬁned IRG as MRF and FRE of 6-20%. As an 
alternative, ATP III also suggested FRE could be calculated without counting risk factors. 
The number of Americans in the IRG using these deﬁnitions was explored.
Methods: The NHANES 1999-2000 data set of 20-79 year old American adults was 
analyzed (N=166 million). Risk factors and FRE were determined for each subject. The 
3 deﬁnitions of IRG and weighted representative populations were determined across 
age deciles.
Results: By the ATP III deﬁnition, only 9.1 million (5.5%) Americans are in the IRG. If a 
FRE of 6-20% is used, the IRG expands to 16.7 million (10.1%). Using a FRE of 6-20% 
without risk factor counting, 27 million (16.2%) are in the IRG. Percentages by age decile 
are in the ﬁgure.
Comment: Only 9.1 million Americans - about 1 in 20 - are at intermediate risk by current 
guidelines. Using the most liberal deﬁnition, the IRG still is much smaller than previous 
estimates. A health policy that directs expensive resources towards clariﬁcation of the 
IRG’s risk may be focusing on a small portion of the population.
 
4:45 p.m.
827-6 Cardiac Catheterization for Intermediate-Risk 
Patients by Health Insurance Payor Status: A Report 
from the American College of Cardiology - National 
Cardiovascular Data Registry (ACC-NCDR)
Henry W. Huang, Richard E. Shaw, California Paciﬁc Medical Center, San Francisco, CA, 
American College of Cardiology, Bethesda, MD
Background: The type of health insurance that patients have may affect the kind of 
medical care they receive. There is no data on whether the use of cardiac catheterization to 
aggressively work-up intermediate-risk patients is dependent on type of health insurance. 
Intermediate-risk patients include those with atypical chest pain (ACP) and an equivocal 
stress test (EST). The purpose of this study was to examine the association between an 
invasive diagnostic approach for coronary disease and different health insurance payors.
Methods: Between 1/1/02 and 12/31/03, data from 940,484 consecutive diagnostic 
cardiac catheterizations were submitted from 341 institutions to the American College 
of Cardiology - National Cardiovascular Data Registry (ACC-NCDR). EST results were 
found in 28,725 (3.1%); 129,402 (13.8%) presented with ACP; 6,732 (0.7%) presented 
with both EST and ACP (EST/ACP). The distribution of the EST/ACP group across payor 
status (government, commercial, HMO and no insurance) was assessed.
Results: Patients presenting with EST/ACP were signiﬁcantly more likely to have 
commercial insurance (38.7% vs. 30.2%; p<0.0001) and less likely to have government 
insurance (42.8% vs. 52.6%; p<0.0001) compared to higher-risk patients not presenting 
with EST/ACP. The EST/ACP group did not differ signiﬁcantly for HMO (14.8% vs. 13.4%; 
p=n.s.) or uninsured (3.7% vs. 3.9%; p=n.s.) payor status compared to the other group.
Conclusions: An aggressive approach for work-up of intermediate-risk patients 
(i.e. cardiac catheterization) was more likely to be associated with commercial health 
insurance, and less likely to be associated with a government payor. Use of cardiac 
catheterization for these patients may reﬂect a higher intensity or even quality of care, and 
may be inﬂuenced by potential reimbursement. Our data may reﬂect falling government 
payments for health care and relatively higher payments from commercial payors.
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827-7 Health Status in Acute Coronary Syndrome
Thomas M. Maddox, Kimberly Reid, John A. Spertus, Mid America Heart Institute, 
Kansas City, MO
Background: The spectrum of acute coronary syndrome (ACS) presentations ranges 
from unstable angina (UA) to ST-elevation myocardial infarction (STEMI). While previous 
investigators have described the differences in mortality outcomes associated with each 
presentation, the association of different ACS presentations with angina frequency, 
physical limitation, and quality of life remains unknown. To address this gap in knowledge, 
we assessed these health status outcomes in a prospective registry of ACS patients at 
hospital admission and one year later.
Methods: Patients in an ACS registry from two hospitals were prospectively classiﬁed 
as having STEMI, non-STEMI, or UA by a blinded review of all clinical information and 
detailed interviews by trained data collectors. Using the Seattle Angina Questionnaire 
(SAQ) and Short Form 12 (SF-12), patients’ health status was assessed at hospital 
admission and one year post-discharge.
Results: Between March 2001 and October 2002, 1199 patients were admitted with 
acute coronary syndrome. 332 (28%) presented with STEMI, 348 (29%) presented with 
NSTEMI, and 519 (48%) presented with UA. On admission, UA patients had worse anginal 
frequency, physical limitation, and quality of life scores (69.1 +/- 20.6, 47.1 +/- 18.8, 35.3 
+/- 11.9), than either NSTEMI patients (78.9 +/- 18, 53.6 +/- 20.1, 38.8 +/- 12.3) or STEMI 
patients (82.8 +/- 14.1, 50.3 +/- 17.5, 42.8 +/- 11.4). One year post-discharge, UA patients 
continued to have worse health status scores (anginal frequency 85.4 +/-24.9, physical 
limitation 79.1 +/- 29.7, quality of life 39.6 +/- 12.0) than either NSTEMI patients (91.7 
+/-17.6, 84.2 +/- 19.7, 44.2 +/- 11.1) or STEMI patients (92.9 +/- 17.0, 83.7 +/- 19.2, 44.3 
+/- 11.2). All p-values were <0.05.
Conclusions: UA patients have worse health status at the time of admission and 
experience signiﬁcantly worse 1-year health status outcomes than either NSTEMI or 
STEMI patients. These ﬁndings stand in direct opposition to the trend of higher mortality 
in NSTEMI and STEMI patients, as compared to UA patients. Further research is needed 
to deﬁne the sources of these differences and to design strategies to improve the health 
status outcomes of UA patients.
5:15 p.m.
827-8 Prediction of Rehospitalization and Death in Advanced 
Heart Failure Patients by Nurses and Physicians
Laura Yamokoski, Rakhi Kilaru, Vic Hasselblad, Debra Moser, Cynthia Binanay, Ginger 
Conway, Jana M. Glotzer, Karen A. Hartman, Carl V. Leier, Lynne W. Stevenson, Ohio 
State University, Columbus, OH
Background: Patients with NYHA class IV heart failure (HF) have a 50% chance of 
hospital readmission and a 20% chance of mortality at 6 mos. We assessed whether 
nurses and physicians can accurately predict these events. 
Methods: Nurses and physicians independently predicted the risk of rehospitalization 
and death of ESCAPE patients (n=433; mean age 56±14 yrs, 74% male, LVEF 19+7%, 
BUN 35 mg/dL, SBP 106±16 mm Hg, creatinine 1.5±0.6 mg/dL) by placing them in 1 of 
4 risk categories: 0-25%, 26-50%, 51-75%, and 76-100%. To compare risk prediction, a 
score was assigned to each category, converted to a log-odds risk, and used in a logistic 
regression model with endpoints of rehospitalization or death. A “best clinical model” was 
generated for comparison. 
Results: Compared with the best clinical model, nurses and physicians both underpredicted 
rehospitalization and death; prediction of death was more accurate. Observed mortalities for 
the nurse categories were 9.7%, 19.6%, 28.3%, and 70.6%; for the physicians they were 
13.4%, 17.8%, 26.6%, and 80.0%. Scores as predictive measures based on the nurses’ 
and physicians’ categories were analyzed (Table). Nurses* were signiﬁcantly better than 
physicians* at predicting patient death, nearly equaling the accuracy of the clinical model.
Conclusion: Nursing assessment can contribute signiﬁcantly to the prognostication of 
patients hospitalized for advanced HF and should be routinely incorporated into patient 
discharge planning.
Comparison of Risk Models for Rehospitalization and Death 
Rater (Clinician) Endpoint Chi-square p c-index
Nurse Rehosp 11.68 0.0006 0.604
Physician Rehosp 15.09 0.0001 0.615
Best clinical model1 Rehosp 24.93 <0.0001 0.683
Nurse Death 31.82* <0.0001 0.714*
Physician Death 18.33* <0.0001 0.649
Best clinical model2 Death 27.74 <0.0001 0.718
1 Includes 6-min walk, pulse pressure, and BUN level
2 Includes 6-min walk, sodium level, BUN level, and age
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1144-181 Improved Discharge Planning With Computerized 
Physician Order Entry System
Joann Goring, Carrie Geisberg, Ted Speroff, Patrick Arbogast, Martha Newton, Lamuel 
Waitman, Renee Stiles, Randolph Miller, Wayne Ray, Marie Grifﬁn, Javed Butler, 
Vanderbilt University, Nashville, TN
Background: Most measures used to assess hospitalized congestive heart failure (CHF) 
and acute myocardial infarction (AMI) patients’ quality of care involves discharge planning. 
This study, we sought to evaluate the effectiveness of computerized physician order entry 
(CPOE) systems in improving discharge planning for hospitalized CHF and AMI patients.
Methods: We studied a total of 286 vs. 290 AMI and 595 vs. 656 CHF discharges in 
the pre-CPOE (7/01-6/02) and CPOE (10/02-9/03) periods respectively. Compliance with 
chosen quality measures was compared between the two periods and within the CPOE 
period among discharges when the CPOE was actually used vs. when it was not.
Results: Smoking cessation counseling (43% vs. 1% for CHF and 62% vs. 21% for 
AMI, both p<0.01) and discharge instructions for CHF (56% vs. 3%, p<0.01) improved 
signiﬁcantly in the CPOE period. Overall 417(63%) of CHF and 183 (63%) of AMI patients 
in the CPOE period were actually discharged using the tools. Compliance with prescription 
of ACEI was 100% for both CHF and AMI among eligible patients when CPOE was used 
compared to 58% and 52% respectively when it was not (p<0.001 for both comparisons). 
Compliance with prescription of aspirin at discharge post-AMI was 100% vs. 83% 
(p<0.001), when the CPOE tool was and was not used. There was a signiﬁcantly higher 
documentation rate of contraindications in the CPOE period. 
Conclusion: CPOE systems signiﬁcantly improved discharge planning. Effective methods 
of rapid implementation and acceptance of these tools by providers requires further study.
1144-182 Combined Optimal Lipid Value Attainment in High-Risk 
Patients Under Managed Care
Eric Stanek, Scott Charland, Bruce Schrader, Chaitanya Sarawate, Vincent Willey, Mark 
Cziraky, Kos Pharmaceuticals, Inc, Weston, FL, Health Core, Inc., Wilmington, DE
Background: Sparse data exist on the concomitant attainment of >1 optimal lipid value. 
We evaluated combined attainment of NCEP ATP-III optimal values for low- and high-
density lipoprotein-cholesterol (LDL-C; HDL-C), and triglyceride (TG), treatment, and risk 
of cardiovascular events in high-risk patients.
Methods: A retrospective cohort analysis of a 1.1M member, southeastern US managed 
care database evaluated patients with a lipid panel from 10/1/99-9/30/00 (index lab), naïve 
to lipid therapy and with plan eligibility ≥12 months pre/post-index date. Patients with pre-
index coronary heart disease, stroke, or peripheral arterial disease, and/or hypertension, 
were selected. Combined optimal lipid value attainment was assessed at index and 
quarterly over 3 years f/u. Cardiovascular event risk was calculated by multivariate logistic 
regression.
Results: Characteristics of selected patients: 50% male, mean age 70 years, 25% 
diabetes mellitus, mean f/u 26±8 months. 
Optimal LDL-C+HDL-C+TG Achieved
Cohort N Index Lab 1 year 3 years
All 30,348 14% 18% 23%
Coronary heart disease 10,752 10% 14% 19%
Peripheral arterial disease 1,652 10% 13% 18%
Stroke 3,186 10% 14% 20%
Hypertension 15,913 20% 24% 28%
Therapy was prescribed to 30% after a lag of 8±9 months post-index lab. Nearly 90% was 
statin alone, and combination therapy <1% despite 30-40% with low HDL-C and/or high 
TG. In 17,289, 2° prevention patients, those achieving 0/3 vs 3/3 optimal lipid values had 
a higher risk of CV events (odds ratio 1.32, 95%CI 1.09-1.59).
Conclusions: In this high-risk managed care cohort, a majority did not achieve combined 
optimal lipid values due to undertreatment, leading to a higher risk of cardiovascular events.
1144-185 Contemporary Patterns of Use of Evidence-based 
Medical Therapy in Older Patients with Myocardial 
Infarction: Results of the PREMIER Registry
Marvin H. Eng, John S. Rumsfeld, Edward P. Havranek, Philip G. Jones, David J. Magid, 
John C. Messenger, John A. Spertus, Saif S. Rathore, Harlan M. Krumholz, Frederick 
A. Masoudi, University of Colorado Health Sciences Center, Denver, CO, Mid-America 
Heart Institute/University of Missouri, Kansas City, Kansas City, MO
Background: Clinical trials and observational studies provide evidence for the use of a 
range of medical treatments in eligible patients of all ages with acute myocardial infarction 
(MI). We assessed age-related variation in the use of evidence-based treatment for MI.
Methods: We studied consecutive patients surviving hospitalization for MI from 19 
US centers enrolled between 1/2003-6/2004 in the PREMIER registry (n=3786). We 
assessed the prescription at hospital discharge of medical treatments in patients without 
drug-speciﬁc contraindications as a function of age. Treatments studied included aspirin, 
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beta-blockers, ACE-inhibitors for patients with LVSD, and HMG Co-A reductase inhibitors 
(statins) for patients with serum LDL>100 mg/dL and statins regardless of LDL.
Results: Prescription rates for aspirin and ACE-inhibitors did not differ signiﬁcantly by 
patient age (Table). Older patients were signiﬁcantly less likely to receive beta-blockers 
or statins.
Conclusions: Age-associated differences in treatment in patients hospitalized with MI 
vary both in their presence and magnitude, with older patients generally less likely to 
receive guideline-recommended medications. Given the particularly high risk for adverse 
events in older patients, these differences in care may have serious implications for 
population outcomes.
 
AGE GROUP
<=64
(n=2,197)
65-74
(n=785)
>=75
(n=804) p
Aspirin 94.0% 94.8% 93.2% 0.4
Beta-blocker 91.7% 91.1% 87.9% 0.008
ACE-inhibitor (LVSD) 81.2% 79.0% 76.8% 0.3
Statin (LDL>100mg/dL) 88.7% 84.5% 78.0% <0.0001
Statin (any LDL) 82.7% 80.5% 72.2% <0.0001
1144-186 Does Time of Day and Day of the Week Affect 
the Receipt of Reperfusion Therapy and Hospital 
Outcomes? The Global Registry of Acute Coronary 
Events
Joel M. Gore, Robert J. Goldberg, Gordon Saperia, David Brieger, Enrique P. Gurﬁnkel, 
Aníbal Campo, Philippe G. Steg, Jeanna Allegrone, Frederick A. Spencer, GRACE 
Investigators, University of Massachusetts Medical School, Worcester, MA, ICYCC 
Favaloro Foundation, Buenos Aires, Argentina
Background It is unclear whether time of hospital presentation affects receipt of coronary 
reperfusion therapy and hospital outcomes.
Methods We examined the relation between day of the week and time of presentation and 
the use of PCI, thrombolytics, both, or neither, and hospital outcomes in 9,284 patients 
with ST elevation acute myocardial infarction (STEMI) included in the multinational 
GRACE registry.
Results Use of PCI was higher during the daytime hours whereas thrombolytic use was 
greater during evening/night-time. Use of primary PCI was highest on weekdays whereas 
use of thrombolytics was highest on weekends. There was no difference in hospital death 
rates by time of day when any type of reperfusion therapy was used. Hospital death rates 
were lowest in patients arriving between 6am and noon if no reperfusion was used. There 
were no differences in hospital death rates for those treated over the weekend vs weekdays, 
regardless of the use of reperfusion. Presentation in heart failure occurred most often from 
midnight to 6am regardless of either use, or type, of reperfusion therapy, with no difference 
for weekend vs weekday. No differences were observed for cardiogenic shock.
Table. Demographics, use of reperfusion therapy, and hospital outcomes 
6am-
noon
noon-
6pm
6pm-
midnight
midnight-
6am P value
Median age (years) 66 66 65 64 0.07
Use of PCI (%) 20.4 19.6 15.3 16.1 <0.0001
Use of thrombolytic (%) 31.3 30.5 32.0 35.0 0.02
Death (%) [no reperfusion] 8.3 11.7 10.1 10.1 0.04
Death (%) [any reperfusion] 5.4 5.9 6.4 6.8 0.50
CHF (%) [no reperfusion] 21.9 20.5 21.1 26.3 0.02
CHF (%) [any reperfusion] 15.9 15.4 17.7 20.4 0.01
Weekdays Weekend
Median age (years) 65.3 65.0 0.04
Use of primary PCI (%) 18.9 16.5 <0.01
Use of thrombolytic (%) 30.9 34.3 <0.01
Death (%) [no reperfusion] 10.1 10.2 0.88
Death (%) [any reperfusion] 6.1 5.8 0.66
CHF (%) [no reperfusion] 22.2 21.3 0.50
CHF (%) [any reperfusion] 16.8 17.1 0.86
Conclusions In patients with STEMI, time of hospital presentation may affect the frequency 
and type of coronary reperfusion received. However, time of day and day of week do not 
have a major impact on hospital outcome regardless of type of reperfusion therapy used.
1144-187 Aspirin in the Primary Prevention of Cardiovascular 
Disease: A Gender-Speciﬁc Meta-Analysis
Jeffrey S. Berger, Carla Roncaglioni, Fausto Avanzini, Gianni Tognoni, Carrie Scharf, 
David L. Brown, Beth Israel Medical Center, New York CIty, NY, Instituto di Richerche 
Farmacologiche “Mario Negri”, Milano, Italy
Background: Aspirin therapy reduces the risk of cardiovascular disease in adults who 
are at increased risk (5-year risk of greater than or equal to 3%). However, it is unclear if 
women derive the same beneﬁt as men. We performed a gender-speciﬁc meta-analysis of 
randomized trials of aspirin in the primary prevention of cardiovascular disease.
Methods: Primary prophylaxis trials of aspirin were identiﬁed by electronic searches of 
the MEDLINE database from 1966 to 2004. Two randomized trials were identiﬁed that 
enrolled women and 5 trials that enrolled men. The random effects model was used 
to combine results from individual trials and calculate estimates of beneﬁts and risks 
associated with therapy. 
Results: Among the 11,466 women randomized, aspirin therapy was associated with a 
statistically signiﬁcant 21% reduction in the risk of vascular events (non-fatal myocardial 
infarction (MI), nonfatal stroke and cardiovascular death) (Odds Ratio (OR) 0.787, 95% 
Conﬁdence Interval (CI) 0.621-0.997, P=0.047). There was no signiﬁcant effect on MI, 
stroke or total mortality. Among the 44,114 men, aspirin therapy was associated with a 
statistically signiﬁcant 32% reduction in the risk of a ﬁrst MI (OR 0.682, 95% CI 0.542-
0.859, P=0.001) and a signiﬁcant 14% reduction in the risk of vascular events (OR 0.865, 
95% CI 0.791-0.944, P=0.001). There was no signiﬁcant effect on stroke or total mortality. 
Women (OR 2.195, 95% CI 1.133-4.252, P=0.020) and men (OR 1.748, 95% CI 1.355-
2.254, P<0.001) were signiﬁcantly more likely to experience major bleeding while on 
aspirin treatment.
Conclusion: Aspirin therapy reduces the incidence of adverse cardiovascular events in 
women and men while increasing the risk of bleeding.
1144-188 Patterns of Use and Potential Impact of Early Beta-
Blocker Therapy in Non-ST-Elevation Myocardial 
Infarctions With and Without Heart Failure: Insights 
From the Global Registry of Acute Coronary Events
Michael Emery, Jose Lopez-Sendon, Philippe Gabriel Steg, Frederick A. Anderson, Jr., 
Omar H. Dabbous, Aliocha Scheuble, Kim A. Eagle, GRACE Investigators, University of 
Michigan Health Systems, Ann Arbor, MI
Background: Early beta-blocker (BB) therapy has been shown to improve outcomes in 
patients with ST-elevation myocardial infarction; however, there is limited data on their 
early use and potential impact in non-ST-elevation myocardial infarction (NSTEMI). Also, 
studies have shown that those presenting with NSTEMI complicated by heart failure (HF) 
are treated less aggressively and have worse outcomes.
Methods: 6769 patients in 94 hospitals from 14 countries with NSTEMI, without 
contraindications to BB, participated in the registry (April 1999 to March 2004). Baseline 
characteristics, in-hospital management, and outcomes were analyzed according to 
the use of oral BB (with or without intravenous BB) versus no BB within 24 hours from 
presentation. Multivariate analysis was performed to assess the potential independent 
beneﬁt of BB on in-hospital death after adjusting for comorbidities using the GRACE risk 
model (C-statistic = 0.83).
Results: 
All NSTEMI NSTEMI with Killip I NSTEMI with Killip II/III
Early BB None Early BB None Early BB None
N (%) 5163 (76.3) 1606 (23.7)* 4572 (78.7) 1238 (21.3)* 591 (61.6) 368 (38.4)*
Age, years (mean ± SD) 66 ± 13 69 ± 13* 65 ± 13 67 ± 13* 73 ± 11 75 ± 11
Killip II/III at admission, % 11.5 22.9* 0 0 100 100
Chronic oral BB, % 39 13* 37 12* 52 14*
In-hospital PCI, % 33 26* 34 30* 23 16*
BB after 1st 24 hours, % 94 44* 94 45* 93 38*
In-hospital Death, % 1.7 4.4* 1.4 2.3* 3.8 11.0*
In-hospital Death, odds 
ratio 0.60 (0.39-0.79) 0.77 (0.48-1.27) 0.40 (0.21-0.63)
*Signiﬁcant (p<0.05)
Patients generally considered to be higher risk were much less likely to receive early BB 
or BB after the ﬁrst 24 hours. Patients in Killip class II or III who did not receive BB had 
higher mortality. This may reﬂect missed potential treatment beneﬁt and/or unmeasured 
comorbidities.
Conclusions: BBs tend to be withheld from patients that appear to be at highest risk 
with NSTEMI, who may in fact beneﬁt from them the most. Early BB therapy may have 
a beneﬁcial impact on in-hospital death and possibly other end-points in all patients 
including those presenting with HF.
1144-189 Is the American Heart Association’s Get with the 
Guidelines (GWTG) Program Associated with 
Improvements in the Quality of Cardiovascular Care in 
Hospitalized Patients Undergoing Revascularization?
Gregg C. Fonarow, Kenneth A. LaBresh, A. Gray Ellrodt, Eric D. Peterson, Patricia Tyler, 
Yuling Hong, Warren Skea, Y. Anita Chen, GWTG Steering Committee and Investigators, 
UCLA Medical Center, Los Angeles, CA, American Heart Association, Dallas, TX
Background: GWTG is a national initiative of the AHA to improve guidelines adherence in 
pts hospitalized with CAD. Whether GWTG is associated with improvements in the quality 
of care in CAD pts undergoing revascularization (ReV) with PCI (with or w/o stenting) or 
CABG to a comparable degree to those managed medically has not been well studied
Methods: Data were collected with a web-based Patient Management Tool providing 
decision support at the point of care, on-demand reporting, and pt education features. 
Data from hospitals for the ﬁrst 30 baseline records plus up to 5 additional quarters were 
analyzed to determine if guideline-driven care impoved over time for 11 quality indicators 
(QI): early aspirin, beta-blocker, and dc ACEI use (AMI pts only); dc aspirin, beta-blocker 
use, smoking cessation, cardiac rehabilitation or exercise Rx, BP < 140/90 mm Hg, and lipid 
measurement and Rx for all pts or those with LDL > 100 mg/dL (all eligible CAD pts).
Results: Data were analyzed from 50,174 pts from 96 hospitals, 26,742 (53%) with no ReV, 
18,634 with PCI (37%) and 4798 (9.6%) CABG. With the exception of ACEI after CABG, ReV 
patients were more likely to be treated at baseline and this persisted post-GWTG intervention. 
Signiﬁcant improvements in 8 of 11 QIs were seen in the medical, PCI and CABG pts.
Conclusions: ReV pts were more likely to receive guideline recommended therapies 
than non-ReV pts. GWTG is associated with comparable improvements in the quality of 
care for hospitalized CAD pts whether undergoing ReV or not.
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Discharge Quality Measures at Baseline and  
5th Quarter Post GWTG 
Quality Measures
Medical
(No ReV)
Baseline
Medical
(No ReV)
Q5
PCI
Baseline
PCI
Q5
CABG
Baseline
CABG
Q5
Total Cohort
Baseline
Total 
Cohort
Q5
Time Trend 
Signiﬁcant 
*
ReV vs 
No ReV 
Signiﬁcant 
#
Discharge Aspirin 86.0% 87.7% 99.3% 99.6% 95.8% 97.4% 92.3% 93.5% #
Discharge Beta 
Blocker 68.7% 82.7% 85.8% 91.7% 83.5% 91.6% 76.9% 87.2% *, #
Discharge ACEI 61.0% 71.3% 67.7% 77.8% 56.6% 63.7% 63.8% 73.6% *, #
Lipid Rx, all CAD 49.3% 55.5% 79.9% 88.2% 70.0% 82.5% 63.1% 70.6% *, #
Lipid Rx, LDL > 
100 mg/dL 54.7% 62.3% 83.3% 90.2% 76.6% 83.2% 70.8% 78.9% *, #
Smoking 
Cessation 54.9% 74.1% 69.1% 87.1% 63.2% 82.9% 62.7% 81.3% *, #
Cardiac 
Rehabilitation 47.7% 63.9% 72.3% 89.4% 83.9% 94.3% 60.5% 76.6% *, #
BP < 140/90 at 
Discharge 70.0% 73.7% 75.9% 81.0% 77.6% 80.1% 72.9% 77.1% #
1144-190 Physical Capacity and Quality of Life Beneﬁts of Phase 
II Outpatient Cardiac Rehabilitation Among the Old-Old, 
the Young-Old, and Adults
Joel W. Hughes, Donna Waecther, James Rosneck, Richard Josephson, Summa Health 
System, Akron, OH, Kent State University, Kent, OH
Background: Therapeutic advances in cardiology and an aging American population 
have resulted in an increase in the ages of potential cardiac rehabilitation (CR) patients. 
It is important to understand whether or not patients of different ages receive similar 
beneﬁts. This study examined gains in physical capacity in CR among the old-old (> 75 
yrs), the young-old (65-75 yrs), and the adult (< 65 yrs), as well as whether or not changes 
in physical capacity predict quality of life at the end of CR.
Methods: The sample included 144 women and 329 men assessed at enrollment in CR 
and after 12 weeks. There were 162 old-old, 156 young-old, and 155 patients less than 65 
yrs old. Functional capacity was estimated in METS using treadmill stress tests. Physical 
functioning (PF) and mental health (MH) quality of life were assessed with the short form 
of the Medical Outcomes Survey (SF36).
Results: Increasing age was associated with lower entry and exit METS (p < .01), but 
patients in each age group exhibited equivalent absolute gains during CR (p > .05). The 
Old-old and patients 65-75 yrs had larger percent increases in METS than younger 
patients (p < .01). After controlling for age, gender, and entry METS, change in METS 
predicted PF and MH at the end of rehabilitation (p < .01). These relationships were not 
inﬂuenced by age (p’s > .05).
Conclusion: The old-old (> 75yrs) and the young-old exhibited similar magnitude gains 
in functional capacity as patients less than 65 yrs. Improved functional capacity predicted 
quality of life, and the relationship was as strong for the old-old and young-old as it was 
for younger patients. It is important not to discriminate against the very elderly on the 
basis of a false perception that they will not beneﬁt from CR. The fact that a third of this 
sample is very elderly is evidence that many such patients will complete CR and do 
beneﬁt from CR.
1144-191 Is Depression a Risk Factor for Mortality Following 
Myocardial Infarction?: A Meta-analysis
Deirdre Lane, Rod S. Taylor, Gregory Y H Lip, Douglas Carroll, University of Birmingham, 
Birmingham, United Kingdom
Background: The numerous observational studies that have examined the association 
between depression following myocardial infarction (MI) and subsequent prognosis have 
produced inconsistent results. A meta-analysis was conducted to determine whether the 
studies implicate depression as an independent risk factor for mortality following MI and, 
if so, the magnitude of the effect.
Methods: Searches of electronic databases (MEDLINE, EMBASE, PSYCHINFO, 
& CINAHL to the end of February 2004), abstracts from national and international 
cardiology and psychology conferences (2002/2003) and dissertation abstracts (using 
a Cochrane review search strategy), identiﬁed 21 studies examining the relationship 
between depression and all-cause mortality (ACM) and cardiac mortality (CM) in MI 
patients. Where multiple accounts of the same cohort of patients were available, only 
the report with the longest follow-up time was included in the analysis to assess the 
association between depression and ACM and CM. Subsequent analyses examining the 
effect of assessment of depression (clinician diagnosis vs. questionnaire) and length of 
follow-up on outcome were also conducted.
Results: Nine studies examined the relationship between depression and ACM, with two 
studies reporting data for CM alone. A further nine studies reported outcome data on both 
ACM and CM. The unadjusted calculated pooled odds ratios (ORs) (95% CI) for ACM 
and CM were 2.02 (1.44-2.82) and 2.13 (1.22-3.73), respectively, indicating a two-fold 
increased risk of death following MI among depressed patients. However, after adjusting 
for potential confounders (age, sex and markers of disease severity), the adjusted pooled 
ORs (95% CI) for both ACM and CM, 1.52 (0.87-2.68) and 0.92 (0.13-6.51), respectively, 
were not statistically signiﬁcant. Irrespective of whether depression was assessed 
by clinician diagnosis or questionnaire or whether follow-up was short- (≤ 6 months), 
medium- (7 to 18 months), or long- (>18 months) term, adjusted analyses failed to detect 
signiﬁcant associations between depression and mortality.
Conclusion: Depression may not be an independent risk factor for mortality following MI.
1144-192 National Mortality Trends Among Nonagenarians 
Undergoing Coronary Artery Bypass Grafting during 
the 1990’s
Roger Kapoor, Mikhail Kosiborod, Judith H. Lichtman, Yun Wang, Lawrence M. Brass, 
Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT, George 
Washigton University School of Medicine, Washington, DC
Background: Coronary artery bypass grafting (CABG) is becoming more common in 
nonagenarians, but little is known about long-term mortality in these patients (pts).
Methods: We evaluated a national sample of fee-for-service Medicare beneﬁciaries who 
underwent CABG from 1993-95 (N=501,906). Pts aged <65 yrs and transferred from 
other facilities were excluded. Pts were stratiﬁed by age (65-69, 70-74, 75-79, 80-89, 
≥90 yrs). Crude 1 and 5-year mortality were compared across age groups using Pearson 
chi-square test.
Results: Among pts undergoing CABG, the proportion of ultra-elderly pts (80-89 and ≥90 
yrs combined) increased from 1993-95 (13%, 14%, 15%, respectively by year). Overall, 
both 1 and 5-year mortality were substantially higher in pts ≥90 yrs. than in younger pts 
(Table, global P for comparison <0.001). During the observation period, 1-year mortality 
changed little in pts aged ≥90 yrs (25%, 28%, 27%, respectively for each year between 
1993-95), while 5-year mortality decreased (59%, 59%, 50%). Trends were similar in 
pts aged 80-89 yrs (1-year mortality for each year between 1993-95: 18%, 17%, 17% 
respectively; 5-year mortality: 40%, 38%, 37% respectively).
Conclusion: Nearly half of all nonagenarians undergoing CABG from 1993-95 survived 
more than 5 yrs after the operation. This survival matches the published life expectancy 
for 90 year olds. This information may be helpful in decision-making about CABG in these 
very elderly patients.
Crude Mortality by Age Group (%) 
Age group 1-year mortality 5-year mortality
65-69 (n=163,797) 7.4 19.1
70-74 (n=153,498) 9.8 23.9
75-79 (n=114,825) 12.7 29.7
80-89 (n=68,579) 17.1 38.2
90 and older (n=1207) 26.7 55.3
1144-193 Increased Vascular Events Following Ischemic Stroke in 
the Stroke-Belt Region
Judith H. Lichtman, Yun Wang, Norrina Allen, Harlan Krumholz, Lawrence Brass, Yale 
University School of Medicine, New Haven, CT
Background: The southeast region of the United States is called the “stroke belt” due to 
increased stroke mortality in these areas. We examined whether similar regional patterns 
exist for vascular events and mortality following an ischemic stroke in the elderly.
Methods: We determined 5-year readmission rates for ischemic stroke, other/TIA or 
hemorrhagic stroke, AMI, heart failure (HF), coronary artery disease (CAD), peripheral 
arterial disease (PAD), any vascular disease, all-cause readmission, and mortality among 
all fee-for-service Medicare patients > 65 years hospitalized with an ischemic stroke in 
1993. The stroke belt includes seven states (AL, AK, GA, MS, NC, TN and SC). Cox-
proportional hazards models were developed to adjust for demographic and comorbid 
factors with censoring for death.
Results: A total of 258,664 index stroke events occured in 1993 (68% age 75+; 58% 
women, and 85% Caucasian). Risk-adjusted readmission rates were higher in the stroke-
belt region for ischemic stroke (RR 1.11, 1.05-1.18), AMI (1.17, 1.08-1.28), CAD (1.09, 
1.02-1.16), vascular disease (RR 1.06, 1.01-1.12), all-cause readmission (1.11, 1.03-
1.18), and mortality (1.05, 1.02-1.07).
Conclusion: Our results are the ﬁrst to demonstrate higher rates of ischemic vascular 
events following stroke in the stroke belt region. Understanding the origins of this regional 
variation may provide insights into new paradigms for therapy and opportunities to reduce 
the public health burden of vascular disease in the elderly.
Outcomes 
(1994-1999) Stroke Belt States Other states Risk-adjusted RR (95%CI)
Readmission % %
Ischemic Stroke 11.11 9.93 1.11 (1.05-1.18)
Other Stroke/TIA 5.87 6.25 0.95 (0.89-1.02)
Hemorrhagic Stroke 0.88 0.87 1.05 (0.92-1.21)
AMI 2.89 2.66 1.17 (1.08-1.28)
CHF 4.73 4.86 0.99 (0.91-1.07)
CAD 6.02 5.82 1.09 (1.02-1.16)
PAD 1.96 2.02 0.99 (0.91-1.09)
Vascular 22.86 21.89 1.06 (1.01-1.12)
All cause 81.44 78.56 1.11 (1.03-1.18)
Mortality
5-year all cause 60.22 60.55 1.05 (1.02-1.07)
Stroke belt states: AL, AK, GA, MS, NC, TN and SC
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1144-194 Overestimation of Cardiac Arrhythmias as the Primary 
Cause Death: Perils of Inaccurate Death Certiﬁcate 
Completion & Impact of Educational Intervention
Dhanunjaya Lakkireddy, K. Basarakodu, A. Kondur, R. Srikanth, J. Vacek, D. Esterbrook, 
R. Markhert, K. Ryschon, S. M. Mohiuddin, Creighton Cardiac Center, Omaha, NE, 
Cleveland Clinic Foundation, Cleveland, OH
Background & Objective: Death certiﬁcates are integral to the development of national 
and state morbidity and mortality databases. In 24-45% of non cardiovascular deaths, 
arrhythmia is wrongly identiﬁed as the cause of death. However, little formal training is 
offered for physicians in this regard. We studied the impact of educational intervention on 
this erroneous practice.
Methods: Two hundred and nineteen physicians from various teaching institutions in the US 
were enrolled in the study and were randomized to one of the two groups (Group-I: interactive 
workshop and Group-II: hand out) after a baseline evaluation of their skills in death certiﬁcate 
completion. A week after the intervention their skills are reassessed and compared.
Results: Overall performance was poor with only 19% of participants scoring in the 
optimal range. Sixty percent of participants incorrectly identiﬁed various arrhythmic causes 
including cardiac arrest (22%), cardiopulmonary arrest (16%), ventricular arrhythmia 
(15%), asystole (5%) and arrhythmia otherwise not speciﬁed (2%). After either of the two 
interventions the incorrect identiﬁcation of arrhythmic causes has signiﬁcantly decreased 
to 25% (p<0.001). Group-I showed a dramatic reduction of incorrect identiﬁcation of 
cardiac causes of death from 56% to 6% (p< 0.001). Group-II had modest but statistically 
signiﬁcant reduction from 66% to 44% (p=0.007). The logistic regression analysis showed 
desire for further training prior to intervention (p<0.001), comfort with own ability after 
intervention (<0.001), intervention through didactic workshop (p<0.001), pre-intervention 
awareness of guidelines (p=0.003) and level of training (p=0.037) were independent 
predictors of change of death certiﬁcate scores from unacceptable to acceptable range.
Conclusion: Death certiﬁcate writing skills of physicians are poor and may be contributing 
to great margin of error to the national mortality ﬁgures. Formal interactive training 
improves the performance and establish that cardiovascular/arrhythmia event is a patho-
physiologic descriptor and is the ﬁnal pathway in death due to any cause.
ORAL CONTRIBUTIONS
844  Improving Quality of Care:  
What Works?
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Orange County Convention Center, Room 230B
10:30 a.m.
844-3 A Randomized Trial Of Reminders Attached To 
Echocardiography Reports To Increase Use Of Beta-
blockers For Patients With Systolic Dysfunction.
Paul A. Heidenreich, Mary Goldstein, Michael Pham, Parisa Gholami, Jayant Nath, 
Christophe Gimmler, J. Edwin Atwood, VA Palo Alto Health Care System, Palo Alto, CA
Background: Although beta-blockers are known to prolong survival for patients with 
reduced left ventricular ejection fraction, their use is suboptimal. We hypothesized that a 
reminder attached to the echocardiography report would increase the use of beta-blockers.
Methods: We randomized 657 consecutive patients undergoing echocardiography with 
reduced left ventricular ejection fraction (<40%) at one of three VA echocardiography 
laboratories to a reminder for use of beta-blockers or no reminder. Patients were excluded 
if they left the health care system (112), or died (53) within three months of randomization. 
The primary outcome was a prescription for a beta-blocker between three and nine 
months following echocardiography.
Results: The mean age of the 492 included patients was 68 years, 99% were male, 75% 
had hypertension, 40% had diabetes, 68% had ischemic heart disease, and 67% had 
a history of heart failure. Angiotensin receptor blockers or converting enzyme inhibitors 
were used in 68% and beta-blockers were used in 50% at randomization. At six months 
following randomization, more patients randomized to the reminder were treated with 
beta-blockers (69%, 172/248), compared to those randomized to no reminder (59%, 
145/244, p=0.02). Carvedilol was used in 25% and metoprolol tartrate in 24%, atenolol in 
13% and metoprolol succinate in 3%.
Conclusions: A reminder attached to the echocardiography report increased the use of 
beta-blockers for patients with depressed LVEF.
 
10:45 a.m.
844-4 Impact of Evidence-Based Heart Failure Therapy Use at 
Hospital Discharge on Treatment Rates During Follow-
Up: A Report From the Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients With Heart 
Failure(OPTIMIZE-HF)
Gregg Fonarow, William T. Abraham, Nancy Albert, Wendy Gattis, Mihai Gheorghiade, 
Barry Greenberg, Chris M. O’Connor, Lilin She, Clyde W. Yancy, James B. Young, UCLA 
Medical Center, Los Angeles, CA
Background: OPTIMIZE-HF is designed to improve medical care and education of hospitalized 
HF pts, and to accelerate use of guideline recommended therapies by initiating them prior to 
discharge (DC). The purpose of this analysis is to assess the impact of ACEI and/or ARB and 
beta-blocker (BB) use at DC on use of these agents 60-90 day follow up (f/u).
Methods: Pts with data on the use of ACEI/ARB or BB at both the index hospitalization 
and f/u time points were studied. Only pts with systolic dysfunction were included. Pts with 
documented contraindications were excluded. Number and frequency of pts treated with 
each drug at time of DC and at 60-90 day f/u are reported.
Results: The analysis included 4,434 pts from 86 hospitals with f/u data. The mean (SD) 
age was 72.1 (14.5), with 50% women, and 44% having ischemic etiology. If discharged 
on a BB, 95% of pts remained on a BB during f/u. Only 32% of pts were being treated with 
a BB during 60-90 day f/u, when not discharged on therapy, OR 42.7 (P<0.0001). A larger 
drop off was observed for ACEI/ARB use. Only 19% of pts were on an ACEI/ARB during 
f/u if not treated at DC, OR 11.6 (P<0.0001).
Conclusions: These data reinforce the importance of initiating evidence-based therapies 
for HF prior to DC. These data also suggest that the majority of HF pts discharged on 
BB tolerate therapy well, and few pts discontinue therapy within 60-90 days. Hospital 
teams should implement processes such as those in OPTIMIZE-HF to ensure the use of 
evidence-based therapies in eligible HF pts prior to discharge.
Table 
Treated at Discharge
(Systolic Dysfunction, No Contraindications)
Treated at 60-90 Day Follow-up
Yes No OR
95% CI
42.7
(95% CI 28.5-63.9)
P<0.0001
Beta Blocker Yes
n=1162 (85.6%)
1106
(95.2%)
56
(4.8%)
Beta Blocker No 
n=196 (14.4%)
62
(31.6%)
134
(68.4%)
11.6
(95% CI 8.35-16.1)
p<0.0001
ACE/ARB Inhibitor Yes
n=1385 (83.9%)
1017
(73.4%)
368
(26.6%)
ACE/ARB Inhibitor No
n=265 (16.1%)
51
(19.3%)
214
(80.7%)
11:00 a.m.
844-5 Evaluation of Computerized Quality Improvement Tool 
to Improve Compliance with AHA/ACC Guidelines 
for Management of CAD and Post-ACS Patients in an 
Outpatient Clinic
James T. Dove, Robert W. Ligon, Scott Smith, Prairie Cardiovascular Consultants, 
Springﬁeld, IL
OBJECTIVES: Several studies have shown that following therapeutic guidelines 
improves patient outcomes and decreases treatment costs. One of the current challenges 
in medicine is developing strategies to improve compliance with guideline directed 
therapy. The purpose of this study was to evaluate a new web-based quality improvement 
tool (QIT) that provides physicians with real-time feedback on guideline compliance.
METHODS: The QIT was developed in a web page format and provides visual cues and 
online access to current ACC/AHA guidelines. Patient’s medications, lab results and past 
medical history are automatically obtained from our electronic medical record (EMR). 
Visual alerts are given to the provider when guidelines are not being followed or patients 
are not at therapeutic goals. Providers are required to document any deviation from 
guideline recommendations. 
RESULTS: Between 01/01/2004 and 8/15/2004 there were 11,741 patients seen in our 
outpatient facilities with a diagnosis of CAD. Documentation on 10,759 pts was done 
through our standard EMR interface and documentation on 982 pts used the QIT. 
Guideline compliance was measured in both groups. Compliance was deﬁned as either 
prescribing the medication or documenting a detailed reason for the exception.
CONCLUSIONS: Computerized access to patient medications, history and laboratory 
information, along with visual reminders and alerts, may provide an effective strategy for 
improving compliance with therapeutic guidelines. 
Use of Quality Improvement Tool-Results
EMR Only 
(N=10,759)
EMR+Quality 
Improvement 
Tool(N=982)
Rx Prescribed 
or Documented 
Exception
Compliance
Rx Prescribed 
or Documented 
Exception
Compliance
ASA 10,102 93.9% 982 100%
Beta Blockers 7839 72.8% 982 100%
ACE/ARB 7566 70.3% 982 100%
Statins 8470 78.7% 982 100%
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844-6 Smoking Cessation in Acute Coronary Syndrome 
Patients
P. Kasi Ramanathan, Jianming Fang, Eva M. Kline-Rogers, Barbara Land, Linda 
Thomas, Richard F. Otten, Yuri Resin, Kim A. Eagle, University of Michigan Health 
Systems, Ann Arbor, MI
Background: In acute coronary syndrome (ACS), smoking cessation rates, demographics 
and management strategies have not been well described. We hypothesized that patients 
who are hospitalized with ACS would have higher smoking cessation rates than any 
currently available therapies. 
Methods: We reviewed the 1098 admissions for ACS who had both admission and six-
month follow-up information on smoking status. 254 of these patients reported active 
smoking on admission. Patients were divided into two categories: continued smoking and 
quit smoking based on 6-month phone interview. Clinical variables, management and 
therapies were evaluated. 
Results: The mean age of the 254 patients was 56 and 65% were male. At 6 months 49.2% 
of patients had quit smoking. Signiﬁcant correlates with smoking cessation were coronary 
artery bypass grafting, pulmonary artery catheter placement, and the use of a ventilator. 
Patients who underwent cardiac rehab had a trend towards quitting smoking. Formal 
counseling during hospitalization did not result in an increase in smoking cessation. 
Conclusions: Patients with ACS had a higher six-month smoking cessation rate than 
published rates in ambulatory practice. More severely ill patients, and patients who 
received cardiac rehab following discharge had higher cessation rates. Cessation rates 
were not different in those who received in-patient smoking counseling compared to those 
who did not.
Table 1. Management of Patients with ACS by Smoking Status 
Clinical 
Variables
Continued 
Smoking
N = 129 (50.8)
Quit 
Smoking
N = 125 (49.2)
Total 
Cohort
N = 254
P - Value
CABG 8 (6.2) 23 (18.4) 31 (12.2) 0.003
PA Catheter 9 (7.0) 19 (15.2) 28 (11.0) 0.036
Ventilator 7 (5.4) 26 (20.8) 33 (13.0) <0.001
Counseling 71 (55.0) 59 (47.2) 130 (51.2) 0.256
Cardiac Rehab 25 (19.4) 37 (29.6) 62 (24.4) 0.062
11:30 a.m.
844-7 Failure to Identify Ischemia on the ECG in the 
Emergency Department is Associated With Lower 
Quality Care for Patients With Acute MI: Results of the 
Emergency Department Quality in Myocardial Infarction 
(EDQMI) Study
Frederick A. Masoudi, David J. Magid, Albert J. Tricomi, P. Michael Ho, Ella E. Lyons, 
Laurie Crounse, Pamela N. Peterson, John S. Rumsfeld, University of Colorado Health 
Sciences Center, Denver, CO, Kaiser Permanente Clinical Research Unit, Denver, CO
Background: ECG interpretation is an important component of the assessment 
of patients presenting to the emergency department (ED) with suspected MI. The 
relationship between the failure to identify ischemic ECG abnormalities and appropriate 
medical therapy for patients with MI is unknown.
Methods: Consecutive patients with MI presenting to 5 community EDs between 7/2000-
6/2002 who had elevated cardiac markers within 24 hours of presentation were enrolled. 
Clinical data and ECG interpretation by the ED physician were collected. ECGs were also 
read by 3 cardiologists blinded to the ED interpretation. ECG ischemia was deﬁned as 
any of the following in 2 contiguous leads: ST-elevation >0.1 mV, ST-depression >0.05 mV, 
or T-wave inversion >0.1 mV. Multivariable analysis was used to assess the relationship 
between the failure to identify ECG ischemia in the ED and the use of aspirin, beta-blockers 
and acute reperfusion (thrombolysis or PCI) in patients without contraindications.
Results: Of 1684 patients, 12.4% had ECG ischemia not identiﬁed by the ED provider. 
Crude and adjusted rates of treatment in ideal patients were markedly lower among those 
with ischemia that was not identiﬁed (Table).
Conclusions: Failure to identify ischemic ECG abnormalities is an important predictor 
of the failure to provide evidence-based care to patients presenting to the ED with MI. 
Systems to improve the accuracy of ECG interpretation in the ED are likely to enhance 
the quality of care and to result in better clinical outcomes.
Treatment in Ideal Patients Without and With Missed Ischemia 
Missed
Ischemia (--)
Missed
Ischemia (+)
p
(unadjusted)
Adjusted OR
(95% CI)
Aspirin 84.1% (1200/1427) 62.8% (128/204) <0.001 0.47 (0.34-0.66)
Beta-blockers 62.9% (428/681) 43.4% (33/76) <0.001 0.54 (0.33-0.88)
Reperfusion 82.6% (309/374) 34.5% (10/29) <0.001 0.13 (0.06-0.28)
11:45 a.m.
844-8 Gender Differences in the Application of Evidence-
Based Therapies for the Treatment of Acute Myocardial 
Infarction: The American College of Cardiology’s 
Guidelines Applied in Practice (GAP) Projects in 
Michigan
Sandeep M. Jani, Cecelia K. Montoye, Benrong Chen, Canopy Roychoudhury, Kim A. 
Eagle, University of Michigan Medical Center, Ann Arbor, MI
The American College of Cardiology’s AMI Guidelines Applied in Practice (GAP) program 
has been shown to raise rates of evidence-based medicine use in AMI patients. However, 
the relative beneﬁt of GAP in men and women has not been investigated.
Methods. Standard orders and a discharge tool were used to improve indicator rates 
in AMI patients in Michigan. Pre-GAP data were collected in the 1 year prior to GAP, 
and post-GAP data were collected in the 3 months following GAP. Multivariate logistic 
regression was used to identify predictors of 30-days and 1-year mortality.
Results. The study sample included 1373 women and 1484 men. Use of evidence-based 
medications pre and post GAP stratiﬁed by gender and according to the use of the tool 
is shown in the table. The tool was used less often with women than with men (27.87% 
v. 33.96%, p=0.003). The GAP tool was associated with a trend toward a reduction in 
mortality at 30-days in men (Adj. OR 0.47, 95% CI 0.17-1.31, p=0.15) and women (Adj. 
OR 0.55, 95% CI 0.23-1.31, p=0.18) and at 1-year in men (Adj. OR 0.62, 95% CI 0.36-
1.06, p=0.08). There was a signiﬁcant reduction in 1-year mortality in women (Adj. OR 
0.46, 95% CI 0.27-0.79, p=0.005).
Conclusion. 1) Use of evidence based therapy can be increased by a simple tool. 2) 
Despite lower use in women, the GAP tool was associated with a reduction of 1-year 
mortality in this group. 3) Higher utilization of the tool has the potential of further improving 
long term outcome in women with AMI.
 
Table. Medication Use by Gender and Pre- and Post-GAP Implementation
Women 
Pre-GAP
Women 
Post-GAP p-value
Men Pre-
GAP
Men Post-
GAP p-value
Medication Use N=889 N=958 N=1003 N=1107
Aspirin within 24 hrs 81.8 86.9 0.0002 87.3 87.6 0.8090
Beta Blockers within 24 
hours 68.1 70.8 0.1177 72.5 74.9 0.1457
Aspirin at Discharge 79.4 87.9 <0.0001 83.2 91.5 <0.0001
Beta Blockers at 
Discharge 80.3 90.5 <0.0001 86.5 92.4 <0.0001
Lipid Lowering Agent at 
Discharge 71.2 73.6 0.1519 74.6 81.6 <0.0001
ACE inhibitor at 
Discharge 78.9 77.8 NS 75.6 83.2 <0.0001
Use of Evidence-Based Medicines at Discharge According to Discharge Tool
No 
Discharge 
Tool
Discharge 
Tool p-value
No 
Discharge 
Tool
Discharge 
Tool p-value
n=691 n=267 n=731 n=376
Aspirin at Discharge 85.90 91.80 0.0830 88.64 95.43 0.0053
Beta Blockers at 
Discharge 90.12 91.11 0.8554 91.84 93.11 0.7056
Lipid Lowering Agent at 
Discharge 67.13 86.30 0.0007 77.27 88.13 0.0126
ACE inhibitor at 
Discharge 76.92 79.59 0.7153 79.63 87.95 0.1164
ACE = Angiotensin Converting Enzyme
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1170  Outcomes of Cardiovascular Care
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 3:30 p.m.-4:30 p.m.
1170-185 Elective Percutaneous Coronary Intervention in 
Outpatients is Safe: a Randomized Trial
Gerlind S. Heyde, Karel T. Koch, Jan G.P. Tijssen, Margriet I. Klees, Marcel G.W. 
Dijkgraaf, Lea M. Dijksman, Robbert J. de Winter, Jan J. Piek, Academic Medical Center, 
Amsterdam, The Netherlands
Background: Performance of percutaneous coronary intervention (PCI) in a day case 
setting might reduce logistic constraints on hospital resources, but data on safety are 
limited. We evaluated safety of same day discharge after elective PCI.
Methods: A total of 800 consecutive patients scheduled for elective PCI were 
prospectively included and randomized one week prior to PCI to same day discharge 
or overnight hospital stay. PCI was performed by the femoral approach with a bolus of 
5000 IU of heparin. The sheath was immediately removed after PCI, followed by 4 hours 
of bedrest and observation. Patients randomized to same day discharge were ambulated 
after this period and discharged. Patients randomized to overnight stay were discharged 
the following day. Extended observation and monitoring could be installed at any time 
before discharge, based on pre-deﬁned clinical and angiographic criteria. Primary 
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endpoints were death, MI, CABG, re-PCI and puncture related complications ocurring 
within 24 hours after PCI. Follow-up lasted 30 days.
Results: 403 patiens were assigned to same day discharge, of whom 77 (19%) were 
identiﬁed for extended observation. 397 patients were assigned to overnight stay, of whom 
85(21%) were identiﬁed for extented observation. Cardiac events did not occur within 24 
hours among patients discharged the same day. One patient discharged the same day was 
re-admitted for a pseudo-aneurysm. In the overnight stay group, 2 patients were admitted 
after discharge for a pseudo-aneurysm. Patients identiﬁed for extended observation (162) 
had 25 cardiac events within 24 hours (same day discharge group: 5 MI, 3 CABG and 1 re-
PCI; overnight stay group: 1 death, 11 MI, 3 CABG and 1 re-PCI) (p=0.22). Within 30 days 
after PCI, the overall rate of cardiac events and puncture related complications was 3.7% in 
the same day discharge group and 5.3% in the overnight stay group (p=0.86).
Conclusion: Outpatient PCI in elective patients using the femoral approach is safe. 
Same day discharge does not lead to additional complications. Triage of patients for 
an extended observation period can be performed adequately, based on clinical and 
procedural criteria.
1170-186 Low Prevalence Of High-risk Coronary Anatomy In 
Obese Patients Undergoing Coronary Angiography: The 
Obesity Paradox Or A Referral Bias?
Ronen Rubinshtein, David A. Halon, Ronen Jaffe, Johnny Shahla, Basil S. Lewis, Lady 
Davis Carmel Medical Center, Haifa, Israel
Background: Obesity is a risk factor for both coronary artery disease (CAD) and 
all cause mortality. Better short term outcome has been reported, however, after 
percutaneous coronary intervention in obese pts. To examine possible mechanisms 
underlying this apparent paradox, we examined the relation between body mass index 
(BMI) and frequency of high-risk coronary anatomy (HRCA) in pts referred for coronary 
angiography (angio) at a single medical center.
Methods: The study group consisted of 928 consecutive pts undergoing angio over 6 
months. HRCA was deﬁned as ≥50% stenosis of the left main coronary artery (LMCA) 
and/or triple vessel disease (TVD) (≥70% narrowings). BMI was classiﬁed as in table and 
BMI ≥30 Kg/M² was deﬁned as obese.
Results: HRCA was found in 56/245 (23%) pts with BMI ≥30 Kg/M² vs 250/683 (37%) in 
pts with BMI <30 Kg/M² (p=0.0002). Prevalence of HRCA was lower in obese pts even if 
we considered as HRCA only TVD with proximal LAD involvement (and/or LM disease) 
35/245(14%) vs 139/683(20%), p=0.03. Obese pts were younger (61.4±10.7 vs 65.3±11.4 
yr, p<0.0001) and had higher prevalence of hypertension and diabetes mellitus (Table).
Conclusions: Obese pts presenting for coronary angiography had: 1. Lower risk coronary 
anatomy. 2. Younger age but 3. Higher prevalence of diabetes mellitus and hypertension. 
These ﬁndings may explain better short-term but worse long-term outcomes in such pts. 
Obese pts are probably referred for angio at an earlier stage of their disease.
HRCA and Risk Factors in Relation to BMI (N=928) 
BMI <21(Low) 21-24 (Normal)
25-29 
(Overweight)
30-34 
(Obese)
≥35 
(Severely 
obese)
P value
N 30 241 412 182 63
HRCA 10(33%) 97(40%) 143(35%) 48(26%) 8(13%) 0.0002
TVD 10(33%) 94(39%) 124(30%) 45(25%) 8(13%) 0.0004
LMCA 4(13%) 20(8%) 49(12%) 13(7%) 2(3%) 0.09
Hypertension 13(43%) 121(50%) 205(50%) 127(70%) 45(71%) <0.0001
Diabetes Mellitus 5(17%) 48(20%) 113(27%) 55(30%) 24(38%) 0.01
1170-187 Reduced 6-month Resource Use And Costs Associated 
With Cilostazol In Patients After Successful Coronary 
Stent Implantation: Results From Crest
Zefeng Zhang, William S. Weintraub, Jovonne K. Foster, Paul Kolm, Karan M. Parker, 
Grant T. Anderson, Claudine Jurkovitz, John S. Douglas, Jr., Emory University, Atlanta, GA
Background: The “Cilostazol for RESTenosis” (CREST) study demonstrated that 
after successful coronary stent implantation, the 6-month restenosis rate was lower in 
the Cilostazol treatment group (relative risk 0.65, 95% conﬁdence interval 0.49, 0.86). 
This beneﬁt of cilostazol in preventing restenosis was achieved with no increase in 
complications. This study considers resource use, cost and cost effectiveness of cilostazol 
in CREST.
Methods: A total of 700 patients were randomized to cilostazol 100 mg twice daily versus 
placebo for 6 months. Resources included re-hospitalizations, medications, outpatient 
diagnostic procedures and emergency room visits. Costs were determined from the 
Medicare fee schedule. Cilostazol was priced at $1.64 a day. Restenosis data was 
available for 526 patients.
Results: Overall, costs of re-hospitalizations, outpatient tests and emergency room visits 
during follow-up were lower for patients randomized to cilostazol, while medication costs 
during follow-up were higher for cilostazol patients. Total follow-up costs remained lower 
for cilostazol, although the difference did not reach signiﬁcance. Cilostazol is a dominant 
strategy (better clinical outcome and cost savings), 87.1% dominant, 0.1% dominated, 
91.6% <$1,000 per restenosis averted.
Conclusions: cilostazol is a dominant strategy in patients with successful coronary stent 
implantation, preventing events, and lowering resource use without increasing cost at 6 
months follow-up.
Cilostazol 
(n=259)
Placebo 
(n=267)
Δ(Cilostazol-
placebo) 95% CI of the Δ
Re-hospitalization Costs $1,998.3 $2,597.2 -$599.0 -$197.6, $1,442.4
Medication Costs 
(exclusive of cilostazol) $1,343.0 $1,310.2 $32.8 -$115.1, $40.7
Outpatient Tests Costs $442.2 $521.6 -$79.3 -$58.3, $201.4
ER Visits Costs $61.9 $166.8 -$104.9 $6.8, $461.8
Cilostazol costs $251.2 $0
Total Follow-up Costs $4,096.6 $4,595.8 -$499.2 -$416.9, $1,374.6
1170-188 Cost-Effectiveness of Intensive Atorvastatin Therapy in 
Patients Following Acute Coronary Syndromes
Michael J. Koren, Sanford J. Schwartz, Michael F. Drummond, Jacksonville Center for 
Clinical Research, Jacksonville, FL
Background: Several recent RCTs have demonstrated the clinical beneﬁt of intensive statin 
therapy. This study was designed to assess the cost-effectiveness of intensive compared to 
standard statin therapy for patients following acute coronary syndrome (ACS).
Methods: We performed incremental cost-effectiveness analyses using data from PROVE-
IT, the ﬁrst head-to-head outcomes RCT comparing two statin regimens (pravastatin 
40 mg [standard] and atorvastatin 80 mg [intensive] daily) in subjects presenting with 
ACS. Endpoints were cost per event avoided and cost per life years gained. Wholesale 
acquisition cost was used to assign the cost of statin medication. Average US hospital 
costs for various diagnoses and procedures (Radensky et al, 2001) were used to calculate 
cost offsets. Finally, we applied these analyses to various likely scenarios, including the 
current US model using branded drug price levels, as well as models using generic price 
against branded prices for standard versus intensive therapy. Indirect (productivity) costs 
(i.e., work days lost, etc) were not considered in the analysis.
Results: In the current US branded market, intensive versus standard statin therapy 
results in cost savings. Using PROVE-IT event rates, intensive therapy saved US $1,137 
per patient in hospitalization and drug costs over the 2-year study, as branded atorvastatin 
was both less expensive and more clinically effective than branded pravastatin. Break-
even analysis showed that intensive therapy could cost up to US $1.30/day more than 
standard care and still result in overall cost savings. If the generic pravastatin price were 
50% of current branded price, intensive atorvastatin therapy would still be cost saving. 
At an incremental cost of US $50,000 per extra life-years gained, the intensive regimen 
would still be cost-effective even if a generic standard regimen were available at no cost.
Conclusion: Intensive atorvastatin treatment compared to a standard statin regimen in ACS 
patients, as observed in PROVE-IT, results in both fewer clinical outcomes and lower health care 
costs considering either branded or generic drug prices and thus is clinically and cost-effective.
1170-190 Prediction of Mortality Following Primary Percutaneous 
Coronary Intervention for Acute Myocardial Infarction: 
The CADILLAC Risk Score
Eugenia Nikolsky, Mandeep Singh, Cindy L. Grines, James E. Tcheng, Eulogio Garcia, 
David A. Cox, Marc Turco, Thomas D. Stuckey, Yingbo Na, Alexandra J. Lansky, Bernard 
J. Gersh, William W. O’Neil, Roxana Mehran, Gregg W. Stone, Cardiovascular Research 
Foundation, New York, NY, Columbia University Medical Center, New York, NY
Background. Accurate risk stratiﬁcation after primary percutaneous coronary intervention 
(PCI) for acute myocardial infarction (AMI) is important. Previous risk scores after 
reperfusion therapy have incorporated clinical and/or angiographic variables but have 
not considered baseline left ventricular ejection function (LVEF). We sought to develop a 
simple risk score for predicting mortality following primary PCI for AMI.
Methods and results. The databases from the two largest multicenter, randomized AMI 
trials of primary PCI were utilized for score derivation (the CADILLAC trial, n=2,082) and 
subsequent validation (the Stent-PAMI trial, n=900). Multivariate logistic regression identiﬁed 
7 independent predictors of 1-year mortality; based on the odds ratio each predictor was 
assigned a weighed value: baseline LVEF <40% (4), Killip class 2/3 (3), renal insufﬁciency 
(3), age >65 years (2 points), anemia (2), triple vessel disease (2), and post-procedural 
TIMI ﬂow (2). The sum of the integers was the total risk score for each patient. Three strata 
of risk were deﬁned (low risk, score 0-2; intermediate risk, score 3-5; and high risk, score 
≥6). In the derivation set, 1-year mortality increased from 0.8% to 4.0% and 13.2% in the 
low, intermediate and high risk groups respectively (Ptrend<0.0001). In the validation dataset, 
increasing risk score was also strongly associated with greater 1-year mortality (0.9%, 4.5% 
and 12.4%, respectively; Ptrend<0.0001). The model demonstrated excellent discriminative 
power survival in the derivation and validation sets (c statistics = 0.83 and 0.81 respectively 
for 30-day mortality and 0.79 and 0.78 respectively for 1-year mortality).
Conclusions. In AMI patients treated with primary PCI, 7 risk factors readily available at 
the time of intervention accurately predict short- and long-term mortality. Baseline LVEF 
is the most powerful predictor of survival and should be incorporated into primary PCI 
risk score models.
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POSTER SESSION
1171  Biomedical Computing, Technology, 
and Outcomes Research
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 3:30 p.m.-4:30 p.m.
1171-189 Compression of Echocardiographic Video Clips  
Using Motion Pictures Expert Group-4 Algorythms:  
a Multicenter Validation Study
Paolo Barbier, Marina Alimento, Giovanni Berna, Fabrizio Celeste, Francesco Gentile, 
Antonio Mantero, Vincenzo Montericco, Manuela Muratori, Centro Cardiologico 
Fondazione “Monzino”, IRCCS, Milano, Italy
Background: Large storage requirements and lengthy transmission times associated with 
Motion Pictures Expert Group(MPEG)-2 lossy compression algorythms affect digital imaging 
use in echocardiography. We sought to validate the newer MPEG-4 lossy algorythms to 
greatly reduce image size, using gold standard human expert assessment.
Methods: Cardiologist experts (7) in echocardiography from 4 level III laboratories blindly 
read 165 randomized uncompressed and compressed 2D (fundamental and II harmonics) 
and color Doppler, video clips (normal and pathologic 1 cardiac cycles) in 3 separate 
sessions. Three MPEG-4 (Microsoft MV9 and V2; DivX Networks 4.11) compression 
algorythms were used at 3 compression levels (0%, 35% and 60%). Mean scores (5 point 
scale) were computed for combined diagnostic content and image quality, and compared 
across the 3 compression levels (uncompressed ﬁles as controls). Repeat scoring of 
uncompressed images tested inter- and intra-observer variability. Images were subdivided 
into “optimal” and “sub-optimal” detail resolution based on uncompressed mean score.
Results: Files decreased from 12-83 MB (uncompressed) to 0.03-2.3 MB (MPEG-4; 1:1051-
1:26 reduction ratios). Both intra- and inter-observer variability SD of differences ranged 0.6-
1.3. Mean scores for MV9, V2 and DivX algorythms were not different from uncompressed 
ﬁles at 0% and 35% compression. At 60% compression, DivX mean score was signiﬁcantly 
reduced (p= .002). At sub-category analysis, the difference was still signiﬁcant for gray-scale 
and fundamental imaging and for optimal resolution, but not for color or II harmonics imaging 
or sub-optimal resolution. At regression analysis (whole database), session sequence, 
detail resolution, compression grade, algorythm, image bitrate, echocardiographic view and 
hertz used all inﬂuenced independently the mean score.
Conclusion: These preliminary data support the use of MPEG-4 algorythms to greatly 
reduce echocardiographic ﬁle sizes and cost, and to enhance image archiving and 
transmission use. Quality evaluation studies should account for the many independent 
variables that affect image quality grading.
1171-191 What Is the Most Efﬁcient Data Extraction Method for 
Quality Improvement and Research in Cardiology? A 
Comparison of REMIND Artiﬁcial Intelligence Software 
Verus Manual Chart Abstraction for Determining ACC/
AHA Guideline Adherence in Non-ST Elevation Acute 
Coronary Syndromes
Ali F. Sonel, Chester Bernie Good, Harsha Rao, Alanna Macioce, Lauren June Wall, 
Radu Stefan Niculescu, Sahtyakama Sandilya, Sriram Krishnan, Prasad Aloni, Bharat 
Rao, Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare 
System, Pittsburgh, PA, Siemens Medical Solutions, USA, Malvern, PA
Introduction: Manual extraction of data for Quality Improvement is tedious, requiring 
signiﬁcant individual training and careful attention to the HIPAA Privacy Rule. Automated 
chart abstraction is an alternative approach that saves time and costs. We compared 
manual chart abstraction from an electronic medical record (VA CPRS EMR System) to 
automated extraction using the REMIND artiﬁcial intelligence software in 327 consecutive 
patients admitted with unstable angina or non-ST elevation myocardial infarction.
Methods: All patient features required by ACC/AHA guidelines for determining eligibility 
for class I recommendations to use ACE inhibitors and glycoprotein IIb/IIIa treatment were 
extracted by both methods. Manual extraction was carried out by well-trained, qualiﬁed 
chart abstractors with prior experience in manual chart abstraction. When both extraction 
results were identical, the result was assumed correct. Disagreements were manually 
adjudicated based on pre-determined deﬁnitions.
Results: Manual extraction and data entry required 136 hours compared to 3 hours 
using the Siemens REMIND software. A total of 2289 data elements were identiﬁed, with 
agreement in 1912 (84%) and disagreement in 377, involving 2.5-35% of patients for 
various parameters. REMIND was found to be correct in 215/377 disagreements (57%) 
and manual extraction was correct in the remaining 43% (162). Based on adjudication, 
guideline adherence for ACE inhibitor and glycoprotein IIb/IIIa receptor antagonist use 
were 58.5% and 38.2% respectively. REMIND identiﬁed adherence at 55.7% and 38.2% 
respectively, which was more accurate than guideline adherence determined by manual 
extraction (64.8% and 33.3%).
Conclusions: REMIND can assess ACC/AHA guideline adherence at least as accurately as 
manual chart abstraction. Use of REMIND for Quality Improvement and research can result in 
signiﬁcant savings, better resource utilization, and may improve data extraction quality.
1171-192 Identiﬁcation of Families With Signiﬁcant Clustering 
of Heart Diseases From a Genealogical Population 
Database
Benjamin D. Horne, Nicola J. Camp, Joseph B. Muhlestein, Lisa A. Cannon-Albright, 
LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: First-degree family history of early coronary artery disease (CAD) and 
myocardial infarction (MI) is prognostic among disease-free individuals. Such a measure 
of risk, though, suffers from biased patient recall and the inability to separate shared 
genetics and environment. This study evaluated death due to CAD, MI, hypertensive 
heart disease (HtnHD), and congestive heart failure (CHF) among both close and distant 
relatives.
Methods: The Utah Population Database (UPDB) contains >2 million individuals with 
genealogy data and 250,000 linked death certiﬁcates. Deaths due to CAD (N=28453), MI 
(N=26468), HtnHD (N=3933), and CHF (N=11784) were studied. Familial Relative Risks 
(FRRs) were assessed for ﬁrst-degree and second-degree relatives. Familiality was also 
evaluated using the genealogical index of familiality (GIF) that considers all relationships 
in the UPDB. Pedigrees with signiﬁcant excesses of cases (p<0.01) were also identiﬁed.
Results: FRRs were only signiﬁcant in both ﬁrst-degree (FRR=1.25, p<0.0001) and 
second-degree (FRR=1.06, p=0.0002) relatives of early age (<65 years) at death MI 
cases. GIF analysis, though, demonstrated excess relatedness (regardless of age) for 
death due to MI (case GIF: 2.93, mean control GIF: 2.73, p<0.001), CHF (2.92 vs. 2.66, 
p<0.001), and borderline for HtnHD (2.86 vs. 2.72, p=0.045), but not for CAD (2.774 
vs. 2.767, p=0.39). For early age at death, GIFs showed greater excess relatedness for 
MI (3.06 vs. 2.54, p<0.001), HtnHD (3.22 vs 2.44, p=0.003), and CHF (2.64 vs. 2.23, 
p=0.003). Many large pedigrees with signiﬁcantly greater than expected disease rates 
were identiﬁed. Ten pedigrees with ≥10 affecteds were found for CHF and 200 pedigrees 
for MI (10 MI pedigrees had ≥25 affecteds).
Conclusions: Death due to MI and CHF demonstrated a heritable component in close 
and distant relatives. For MI, HtnHD, and CHF, excess relatedness was more pronounced 
among those dying at an early age, suggesting that gene discovery may be most effective 
among early-onset cases. Individual pedigrees with signiﬁcant excess of MI and CHF 
deaths beyond the expected suggest that the UPDB resource has potential for the 
discovery of genes for these disorders.
1171-193 Utility of a Bayesian Updating Computer Tool to Monitor 
Safety Data in Real Time: An Example Evaluating 
Subacute Stent Thrombosis for the CYPHER Drug 
Eluting Stent
Michael E. Matheny, Leo Chi-chiu Kum, Lucila Ohno-Machado, Frederic S. Resnic, 
Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, Health Sciences & 
Technology, Massachusetts Institute of Technology, Boston, MA
Background: Low event rates and rapid evolution of technology create challenges for 
safety monitoring in interventional cardiology. A Bayesian method incorporates previous 
information (priors) into risk estimates and updates estimates over time as clinical data 
are accrued, allowing the potential detection of safety issues earlier than a corresponding 
frequentist analysis. We explore the feasibility of a software monitoring tool that uses the 
Bayesian method to detect signiﬁcant changes in event rates.
Methods: Our software tool evaluated CYPHER subacute stent thrombosis (SAT) rates 
at our center. This system includes a web-based user interface and an SQL database 
to perform the data manipulation and analysis. For any new procedure or product, initial 
risk estimates (priors) are calculated using the FDA approval data. We used data from 
the SIRIUS and RAVEL (RCT) trials in this example. The risk stratiﬁcation model was 
based on previously published SAT rates for low risk bare metal stent (BMS) data. The 
system calculates updated risk estimates over time, and displayed tabular and graphical 
summaries in a web-based interface.
Results: There was 1 SAT event in 653 procedures in the RCT data (prior). The risk 
stratiﬁcation model was validated using BMS data available from our center (area under 
the ROC curve=0.81). Single center SAT rates for 1617 DES cases were evaluated from 
4/03 to 7/04 at monthly intervals. The observed SAT rates were 0.23% (2/887) and 1.1% 
(8/730) for the low risk and high risk groups, respectively. Initial risk estimates for SAT 
were 0.15% and 0.77%. Final risk estimates were 0.17% (0.04-0.47) and 1.1% (0.5-1.9). 
Early events in the low risk group caused ﬂuctuations in the risk estimate, but the risk did 
not exceed 0.23%. Risk estimates in the high risk group did not exceed 1.2%.
Conclusion: The example analysis conﬁrmed that CYPHER SAT rates were within 
acceptably predicted ranges for low and high risk patients at our center. Our results 
suggest that it is feasible to use a system based on Bayesian updating to perform real 
time monitoring of the safety of newly developed technologies. The system is structured 
to provide ﬂexible monitoring options for any new device or procedure.
1171-194 Using Automated Clinical Data on Admission to Predict 
Mortality Among Patients Hospitalized for Acute 
Myocardial Infarction
Ying Tabak, Stephen Kurtz, Richard Johannes, Cardinal Health - DCI (MediQual), 
Marlborough, MA
Background: Research models predicting mortality have not been widely adopted 
due to the cost of chart abstraction. A cost effective model is critical to large scale 
implementations of quantitative decision support.
Objective: Develop and validate a mortality model based on admission severity using 
automated LAB data and supplementing with UB92 data for demographics, discharge 
status, and comorbidities. The value of vital signs (VS), altered mental status (AMS), and 
ejection fraction (EF) that were not automated, was also analyzed.
Methods: A model was derived from 16,654 (1,361 deaths) AMI admissions across 18 
teaching and 26 non-teaching hospitals that exported LAB data to Atlas TM (MediQual) in 
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2000-01. Multiple levels of LAB & VS were crafted per literature and empiric examinations. 
Demographics, LAB, VS, comorbidities (identiﬁed by 6th digit ICD-9 coding) were entered 
into logistic regressions. ROC assessed model ﬁt. Bootstrapping validated the model 
internally. Manually abstracted data (n = 67,927, 5,673 deaths) from 180 hospitals validated 
the model externally. Results are presented as odds ratios & 95% conﬁdence intervals.
Results: Median age was 71. Mortality was 8.2%. Signiﬁcant predictors included age, 
Troponin I > 12 or CK MB > 125 (1.2, 1.1-1.3), albumin < 2.5 g/dl (1.7, 1.5-2.0), glucose 
< 71 or > 165 mg/dl (1.3, 1.2-1.4), pH arterial < 7.21 (3.3, 3.0-3.8), pCO2 < 36 mm Hg 
(1.9, 1.8-2.1), platelets < 115k / mm3 (1.3, 1.2-1.5), total bilirubin > .08 mg/dl (1.2, 1.1-1.3), 
creatinine > 2.5 mg/dl (1.6, 1.4-1.7), systolic BP < 80 mm Hg (2.8, 2.6-3.1), temperature < 
96 F° (1.4, 1.3-1.6), AMS (5.4, 4.9-5.9), cancer (2.4, 2.0-3.0), & EF < 25% (1.7, 1.5-1.9). 
The ROCs for the derivative & validation models were .87 & .86 respectively.
Conclusions: LAB provides objective and precise measures of acute pathophysiologic 
conditions. Severe LAB derangements on admission predict mortality. VS, AMS, and EF 
are signiﬁcant and should be automated. Pathophysiologic variables commonly measured 
on admission can generate a parsimonious and clinically plausible model with excellent 
accuracy. Based mainly on automated data, this model is cost effective to implement for 
AMI monitoring and outcome reporting.
ORAL CONTRIBUTIONS
870  Treatment Outcomes for Patients With 
Coronary Artery Disease
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 230B
8:30 a.m.
870-3 The Relation Between Angina, Treatment and Quality of 
Life in Cardiac Patients
Patricia A. Cowper, Elizabeth R. DeLong, Barbara A. Lytle, Susan Mayhan, Eric D. 
Peterson, Duke University Medical Center, Durham, NC
Background: In many cases, a major goal of cardiac therapy is to relieve discomfort 
from angina, even if survival is not affected. The effect of therapies on angina frequency, 
functional status and quality of life (QOL) has not been fully explored. 
Methods: Using regression analysis, we examined (i) the effect of angina frequency 
(Seattle Angina Questionnaire (SAQ)) on health related QOL (SF-36 physical (PCS), 
mental (MCS) and subscales) and (ii) the extent to which therapies that relieve angina 
improve QOL among patients catheterized at Duke Medical Center between 4/98 and 
4/01 with signiﬁcant CAD (n=1,641).
Results: The median age of patients was 68 years (range=45-93). Patients with angina at 
baseline (65%) had signiﬁcantly lower QOL than patients without angina (mean PCS=36 
vs 42, p<.001; mean MCS=46 vs 51, p<.001). Two thirds of patients were revascularized 
(CABG=35%, PCI=36%), with the remainder (29%) receiving only medical therapy. At six 
months, clinically signiﬁcant improvements were reported by 47% of patients in PCS (Δ 
= 3.8) and by 35% in MCS (Δ = 7.2). Improvements in QOL were signiﬁcantly related to 
reductions in angina relief, regardless of treatment (PCS shown in Figure). The effect of 
angina on QOL persisted after adjusting for baseline QOL, patient factors, and type of 
treatment. 
Conclusion: Therapies that relieve angina can markedly improve the QOL of cardiac 
patients. To optimize outcomes, angina relief should be a primary consideration in 
treatment selection. 
8:45 a.m.
870-4 Depression in Women Improves After Coronary Artery 
Bypass Graft Surgery
Rachel H. Mitchell, Stephanie J. Brister, Robert P. Nolan, Paula Harvey, Sarah E. Romans, 
Gary Rodin, Emma K. Robertson, Beth L. Abramson, Donna E. Stewart, University Health 
Network, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada
Introduction: Depression is an independent predictor of mortality post coronary artery 
bypass graft (CABG) surgery. Limited research indicates that women, as compared to 
men, experience a worsening of depressive symptoms after CABG surgery. This study 
investigates sex differences in depression during the recovery period after CABG surgery.
Methods: We prospectively followed 130 consecutive patients (69 men, 60 women) 
undergoing elective, isolated, ﬁrst CABG surgery between July 2003 and April 2004. 
Patients were interviewed ≤28 days before surgery and between 6 to 12 weeks after 
surgery. Patients completed a battery of questionnaires including the Beck Depression 
Inventory (BDI) and the ENRICHD Social Support Inventory. Relevant medical data were 
retrieved from patient charts and a Total Risk Score based on the Northern New England 
Cardiovascular Disease Study Group model was calculated for each patient. Multivariable 
analyses were conducted with repeated-measures ANOVA and ANCOVA with multiple 
imputation of the missing data.
Results: Women were signiﬁcantly more depressed than men at baseline (BDI of 12.2 ± 
8.1 in women versus 8.0 ± 7.0 in men, p = 0.003) but not post CABG (BDI of 7.9 ± 6.1 in 
women versus 7.2 ± 6.4 in men, p = 0.53). Depression in both men and women improved 
after surgery, however, there was a signiﬁcant sex by time interaction with women 
improving almost 5-fold more than men (Mean decrease in BDI of 3.4 ± 7.0 in women 
versus 0.7 ± 6.5 in men, p = 0.009). When the model was adjusted for age, education, 
social support and total risk score, however, the interaction was no longer signiﬁcant.
Conclusions: Women were more depressed than men pre CABG; but improved to a 
level comparable to men post CABG. Women’s signiﬁcant improvement in depression 
scores, as compared to men’s, may be explained by women’s more severe baseline 
level from which to improve and sex differences in sociodemographics and health status. 
More studies including large samples of women are needed to improve patient care and 
outcomes from CABG surgery.
9:00 a.m.
870-5 Cost Comparison Of Four Revascularization 
Procedures In Patients With Multi-Vessel Coronary 
Artery Disease
Andre Lamy, Xiaoyin Wang, Michael J. Rokoss, Adel Dyub, Amiram Gafni, McMaster 
University, Hamilton, ON, Canada
Background: To assess direct medical costs and clinical outcomes of 4 revascularization 
strategies in managing patients with multi-vessel coronary artery disease: off-pump 
CABG or on-pump CABG, PCI with drug-eluted stent (DES) or bare-metal stent (BMS).
Method: A decision analytic model was developed describing the 4 strategies from 
initial procedure to 1-year. Monte Carlo simulation technique was used to account for 
uncertainty over the cost variables. Clinical outcome was the composite event of death, 
MI and stroke derived from systematic view of randomized trials comparing off- vs. on-
pump CABG, multi-vessel stenting vs. CABG, and DES vs. BMS. Resources utilization 
estimations were based on Canadian resource use pattern from a third party payer’s 
perspective. Unit costs were based on Hamilton Health Sciences Case-Costing system 
and were adjusted to 2003 Canadian dollars.
Results: Mean and standard deviation of estimated costs and event rates are presented 
in the table. Sensitivity analysis shown that the result was sensitive to DES cost. 
Initial Procedure On-Pump Off-Pump BMS DES
Costs $12,267 ($153) $10,659 ($180) $7,004 ($2291) $11,298 ($569)
Composite Event 0.138 (0.034) 0.099 (0.029) 0.061 (0.024) 0.061 (0.024)
One Year
Total Costs $13,127 ($317) $11,415 ($328) $9,310 ($563) $12,262 ($667)
Total Composite Event 0.200 (0.040) 0.153 (0.035) 0.133 (0.034) 0.132 (0.033)
Conclusion: BMS is the dominant strategy in both initial intervention and at 1-year despite 
a higher rate of repeat revascularization and associated additional costs. However, BMS 
is now largely ignored in favor of DES. Thus our desire to reduce repeat revascularization 
carries a signiﬁcant impact on health expenditures without improving death, MI or stroke. 
Health care funding could be invested more wisely and/or DES costs should be lowered 
to a competitive level.
9:15 a.m.
870-6 Population Trends in Treatment and Outcomes in 
Patients with Congestive Heart Failure: The Minnesota 
Heart Survey
Alan K. Berger, Cheryl A. Barber, Susan J. Duval, Russell V. Luepker, University of 
Minnesota, Minneapolis, MN
Background: The pharmacologic treatment of patients with congestive heart failure 
(CHF) has evolved over the past decade. There is a paucity of literature regarding the 
changing practice patterns and their impact on post-discharge mortality.
Hypothesis: Post-discharge mortality for CHF patients declined between 1995 and 2000 
and this mortality reduction is associated with the increased use of recommended CHF 
therapies.
Methods: We analyzed data from the Minnesota Heart Survey, a population study that 
abstracted a random sample of all medical records of hospitalized CHF patients in 1995 
and 2000 in the Minneapolis-St. Paul metropolitan area. Post-discharge mortality was 
analyzed using the chi-square test. Stepwise logistic regression was used to assess the 
impact of sampling year on mortality. Geometric means of hospital lengths of stay (LOS) 
were compared using the t-test.
Results: Using the Framingham criteria, we identiﬁed 2,480 patients, age 30-79, with 
CHF in 1995 and 1,988 patients with CHF in 2000. In-hospital mortality decreased from 
8.1% in 1995 to 5.9% in 2000 (p=0.006) and 1 week (10.2% vs. 7.3%, p=0.0008) or 1 
month (14.0% vs. 10.2%, p=0.0002). Between 1995 and 2000 there was a slight increase 
in the use of angiotensin converting enzyme inhibitors [ACE-I] (49.8% vs 51.4%, p=NS) at 
discharge and a marked increase in the use of angiotensin receptor blockers [ARB] (0.7% 
vs. 7.3%, p<0.0001) and beta blockers [BB] (14.4% vs 46.9%, p<0.0001). Mean LOS was 
unchanged between 1995 and 2000 (2.3 vs. 2.1 days, p=0.83). There was a 29% (odds 
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ratio [OR] = 0.71, 95% conﬁdence interval [CI]: 0.59, 0.85) reduction in one-month age 
and gender adjusted mortality in 2000 compared to 1995. The sequential addition of ACE-
I (OR 0.71; 95% CI: 0.59, 0.86), ARB (OR 0.81; 95% CI: 0.66, 0.98) and BB (OR 1.12; 
95% CI: 0.91, 1.37) accounted for the beneﬁt of hospitalization in 2000.
Conclusions: Both in-hospital and post-discharge mortality in CHF patients declined in 
spite of a stable hospital LOS between 1995 and 2000. The increased utilization of ACE-I, 
ARB, and BB therapy contributed signiﬁcantly to the reduction in post-discharge mortality.
9:30 a.m.
870-7 The Risk of Bleeding Complications After Different 
Doses of Aspirin: A post-hoc Analysis of 192,036 
Patients Enrolled in 31 Randomized Controlled Trials
Victor L. Serebruany, Steven R. Steinhubl, Peter B. Berger, Alex I. Malinin, Jeffrey S. 
Baggish, Deepak L. Bhatt, Eric J. Topol, HeartDrug Research, Towson, MD, Cleveland 
Clinic, Cleveland, OH
Background: Despite the proven life-saving clinical beneﬁts, aspirin (ASA) therapy is 
associated with an increased risk of bleeding, especially for the conventional (325 mg) 
daily dose. We determined and compared the risk of hemorrhage for the low (<100 mg), 
moderate (100-200mg), and high (>200 mg) doses of ASA.
Methods: Data from clinical trials published 1988-2003 in English were retrieved from 
MEDLINE, OVID, and CARDIOSOURCE. Only those studies in which patients had clinical 
follow-up for at least one month and in which a full description of hemorrhagic complications 
was reported were included. Information on sample size, study design, duration, ASA dose, 
patient characteristics and bleeding severity was independently and blindly reviewed. Data 
from 31 clinical trials with a total of 192,036 patients met the quality criteria, and were analyzed. 
Bleeds were classiﬁed as major (Mj), minor (Mn), hemorrhagic stroke (HS), gastrointestinal 
(GI), fatal / life threatening (FLT), and total (T). The rates, variance estimate, and conﬁdence 
intervals were calculated for each ASA dose dependent on a bleeding type.
Results: Low dose (<100 mg/day) ASA was associated with the lowest risk of bleeding 
(Mj -3.26%, Mn - 1.71%, HS - 0.24%, GI - 0.97%, FLT - 0.27%, for the T - 3.26%). 
Moderate daily dose of ASA (100-200mg) was associated with the low risk for Mj (1.56%), 
and FLT (0.46%) bleeding complications, while the rate of Mn (6.75%), GI (2.4%), and 
T (11.31%) hemorrhagic events was high. The greatest rate of bleeding complications 
was associated with the higher (>200 mg) ASA doses, however the HS (0.47%) were 
signiﬁcantly (p=0.007) higher in the 100-200mg/daily cohort.
Conclusion: Despite substantial differences in the reporting patterns of bleeding 
complications, low dose (<100 mg) ASA were associated with the lowest risk. Doses of 
ASA between 100 - 200 mg caused a relatively high hemorrhagic event rate, especially 
with regard of minor, gastrointestinal, total bleedings, and stroke. These ﬁndings should 
be considered when using combination antiplatelet or/and anticoagulant therapy with 
ASA, especially with the daily dose over 100 mg.
9:45 a.m.
870-8 Aspirin With Oral Anticoagulants: Results From The 
Stroke Prevention Using An Oral Thrombin Inhibitor In 
Atrial Fibrillation (SPORTIF) Program
Greg C. Flaker, Jay Horrow, Michael Gruber, Stephen Goldman, Stuart Connolly, Stuart 
Connolly, University of Missouri-Columbia, Columbia, MO, University of Wisconsin-
Madison, Madison, WI
BACKGROUND: Aspirin (ASA) may be used with warfarin in patients with atrial ﬁbrillation 
at high risk for ischemic events. There are few data proving efﬁcacy and bleeding is more 
likely with combination therapy.
METHODS: The SPORTIF III and V trials demonstrated the non-inferiority of ximelagatran 
compared to warfarin for stroke prevention in AF. ASA use was allowed (<100 mg/day per 
protocol) in selected patients.
RESULTS: 1,012 patients received ASA > 50% of study days. They were more often male 
(76.4 % vs. 68.1 %, p < 0.01) and more often had a previous stroke/TIA (25.6% vs. 20.3%, 
p < 0.01) and coronary artery disease (69.3% vs. 40.9%, p < 0.01). 
n
Stroke/Systemic 
embolism n(%/patient- 
year)
Major bleeding n 
(%/patient- year)
XIMELAGATRAN + No ASA 3120 58 (1.4%) 78 (1.9%)
XIMELAGATRAN +ASA 531 12 (1.7%) 14 (2.0%)
WARFARIN + No ASA 3172 69 (1.6%) 100 (2.3%)
WARFARIN +ASA 481 11 (1.7%) 25 (3.9%)
After adjustment for baseline differences, the only outcome variable of signiﬁcance was 
major bleeding which was more common in patients in whom ASA was added to warfarin 
(HR 1.59, 95% CI 1.01, 2.49, p = 0.05).
CONCLUSIONS: ASA was used with oral anticoagulants in 13.9% of this atrial ﬁbrillation 
population, more commonly in patients at higher risk for stroke. No reduction in stroke or 
systemic embolism could be detected. Bleeding risks are higher when ASA is added to 
warfarin.
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